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1. INTRODUCTION 
 
1.1. COLON TARGETED DRUG DELIVERY SYSTEM   
                                                                                  (Asha patel et al., 2011). 
Colon is being extensively investigated as a drug delivery site. Colon targeted 
drug delivery system (CTDDS) has been developed by means of one or more controlled 
released mechanisms. It is convenient for treating localized colonic diseases, i.e. 
Ulcerative colitis, Crohn’s diseases and constipation etc. 
Its potential applications include Chronotherapy, Prophylaxis of colon cancer and 
treatment of Nicotine addiction. The treatment of Inflammatory Bowel Disease (IBD) 
with anti inflammatory drugs is particularly improved by local delivery to bowel by using 
CTDDS. For successful colon specific drug delivery, many physiological barriers must 
be overcome; the major one is being absorption or degradation of the active drug in the 
upper part of the GIT. The minor is disease state, which can potentially alter the delivery 
and absorption characteristics of drugs from the colon.  
The CTDDS should protect the drug from the absorption and degradation in the 
stomach and small intestine, the drug should be absorbed only at the colonic site. The 
colon is rich in lymphoid tissue, uptake of antigens into the mast cells of colonic mucosa 
produces rapid local production of antibodies and this helps in efficient vaccine delivery. 
The colon is a suitable absorption site for peptides and protein drugs. 
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1.1.1.  Need Of Targeting: 
 It ensures direct treatment at the disease site, lower dosing and fewer systemic 
side effects.  
 It allows oral administration of peptide and protein drugs.   
 Both local or systemic drug delivery could be achieved, topical treatment of 
inflammatory bowel disease, e.g. ulcerative colitis or Crohn’s disease.  
 A number of others serious diseases of the colon, e.g. colorectal cancer, might 
also be capable of being treated more effectively if drugs were targeted to the 
colon.  
 Formulations for colonic delivery are also suitable for delivery of drugs which are 
polar and/or susceptible to chemical and enzymatic degradation in the upper GI 
tract, highly affected by hepatic metabolism, in particular, therapeutic proteins 
and peptides. 
1.1.2. Therapeutic Advantages of Targeting: 
It offers the following therapeutic advantages: 
 Minimizing extensive first pass metabolism of steroids. 
 Preventing the gastric irritation produced by oral administration of NSAIDS. 
 Improved therapy of diseases susceptible to diurnal rhythm. 
 Delayed release of drugs to treat angina, asthma and rheumatoid arthritis. 
 Potential for oral delivery of proteins, peptides and other GI liable drugs. 
 By producing the ‘friendlier’ for peptides and proteins when compared to upper 
GI tract. 
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The therapy of various disease conditions can be improved by colon specific drug 
delivery systems employing various mechanisms of release, which is shown in  
  Table 1: Showing target sites and disease occurs at sites. 
 
Delayed systemic absorption of drugs via colonic delivery is advisable for 
Chronotherapy of diseases such as asthma, hypertension, cardiac arrhythmias, rheumatoid 
arthritis or inflammation, which are affected by circadian rhythms. These diseases are 
characterized by night time or early smorning symptoms. These types of approaches are 
beneficial for nocturnal release of drug, which in turn may provide considerable relief to 
the patients while they are resting. 
The mode of drug release from colon-targeted biopolymer systems can include 
one or more of the following mechanisms 
Target site 
 
Disease condition 
 
Drugs and Active agents 
 
 
TOPICAL 
ACTION 
Inflammatory Bowel 
disease, Irritable bowel 
Syndrome, Chronic 
Pancreatitis, and 
Crohn’s disease. 
Hydrocortisone, 
Budenoside,Prednisolone,Sulfasalazine, 
Olsalazine, Mesalazine and 
Balsalazide. 
 
LOCAL ACTION 
 
Pancreoctomy and 
Crystal fibrosis, 
Colorectal cancer 
 
Digestive enzymes supplements, 5-
Flourouracil. 
 
 
SYSTEMIC 
ACTION 
To prevent gastric 
irritation 
To prevent first pass 
metabolism for orally 
ingested drugs 
Orally delivered 
peptides 
Orally delivered 
vaccines 
 NSAIDS 
Steroids 
 
Insulin 
Typhoid 
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                                      1. Diffusion 
                                      2. Polymer erosion 
                                      3. Microbial degradation 
                                      4. Enzymatic degradation (mammalian and/or bacterial) 
In addition, drug solubility and formulation of polymer mixes play important roles in 
determining the extent of drug delivery and release in the colon. 
  Two broad categories of biopolymers have been employed for formulating 
colonic systems: 
                                        (1) Biodegradable and  
                                        (2) Non biodegradable polymers 
 
1.1.3. Limitations of Colon targeting:                                     
                                                                                                 
To achieve successful colon targeting it should overcome the following 
limitations  
The location at the distal portion of the alimentary canal, the colon is difficult to access. 
 Successful delivery requires the drug to be in solution before it arrives in the 
colon, but the fluid content in the colon is lower and more viscous than in upper 
GIT, which is the limiting factor for poorly soluble drugs. 
 Lower surface area and relative tightness of the tight junctions in the colon can 
restrict drug transport across the mucosa in to the systemic circulation. 
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1.1.4. General considerations for designing of colon targeting formulations: 
  To achieve a desired therapeutic action of dosage form, it is necessary to design a 
suitable formulation with suitable qualities. In general, delayed release dosage forms are 
designed to provide a burst release or a sustained/ prolonged release once they reach 
colon.                                                                                                                                                                                                                                 
Various factors includes are 
 Pathology and pattern of diseases, especially the affected parts of lower GIT or, 
Physiology and physiological composition of the healthy colon if the formulation 
is not intended for localized treatment. 
 Physicochemical properties and biopharmaceutical properties of the drug such as 
solubility, stability and permeability at the intended site of delivery, and the 
desired release profile of the active ingredient. 
 Formulation of drugs for colon specific delivery requires careful consideration of 
dissolution of and / or release rate in the colon fluids. Due to the presence of less fluid 
content in large intestine than in small intestine the dissolution and release rate from the 
formulations decreases. The poor dissolution and release rate may in turn lead to lower 
systemic availability of drugs. These issues could be more problematic when the drug 
candidate is poorly water soluble and / or require higher doses for therapy. Consequently, 
such drugs need to be delivered in pre solubilized form, or formulation should be targeted 
for proximal colon, which has more fluid than in the distal colon. Aside from drug 
solubility, the stability of the drug in the colonic environment is a further factor that 
warrants attention. The drug could bind in a nonspecific manner to dietary residues, 
intestinal secretions, mucus or general fecal matter, thereby reducing the concentration of 
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free drug. Moreover, the resident micro-flora could also affect colonic performance via 
degradation of the drug. 
1.2. General anatomy and physiology of colon: 
                                                                             (Akhil guptha et al., 2011) 
        The GI tract is divided into stomach, small intestine and large intestine. The large 
intestine extending from the ileocecal junction to the anus is divided in to three main 
parts. These are the colon, the rectum and anal canal. 
        The entire colon is about 5 feet (150 cm) long, and is divided in to five major 
segments. Peritoneal folds called as mesentery which is supported by ascending and 
descending colon. The right colon consists of the caecum, ascending colon, hepatic 
flexure and the right half of the transverse colon and the values were shown in Table 2. 
The left colon contain the left half of the transverse colon, descending colon, splenic 
flexure and sigmoid.  
  The major function of the colon is the creation of suitable environment for the 
growth of colonic microorganisms, storage reservoir of fecal contents, expulsion of the 
contents of the colon at an appropriate time and absorption of potassium and water from 
the lumen. The absorptive capacity is very high, each about 2000ml of fluid enters the 
colon through the ileocecal valve from which more than 90% of the fluid is absorbed. On 
average, it has been estimated that colon contains only about 220 gm of wet material 
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equivalent to just 35 gm of dry matter. The majority of this dry matter is bacteria .The 
colon tissue containing the vile, lymph, muscle, nerves, vessels. 
                            Fig. 1: Anatomy of the three parts of colon 
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                                      Fig. 2: Main features of the colon 
            Different properties of GIT were given in (Table 2) and different enzymes present 
in colon, which are responsible for microbial degradation, were reported by Vincent et al 
(2002). 
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      Table 2: Properties of Gastro Intestinal Tract:  
S.No. Region of GIT Property Measured 
value(cm) 
1 Total GIT Surface area 2-106 
2 Small intestine 
-Duodenum 
-Jejunum 
-Ileum 
 
Length 
 
 
20-30 
150-250 
200-350 
3 Large intestine 
-Cecum 
-Ascending colon 
-Descending colon 
-Transverse colon 
-Sigmoid colon 
-Rectum 
-Anal canal 
 
 
 
Length 
 
 
 
6-7 
20 
45 
30 
40 
12 
3 
4  
Small intestine 
Large intestine 
 
Internal diameter 
 
3-4 
6 
5 Stomach 
Duodenum 
Jejunum 
Ileum 
Colon 
Rectum 
 
PH 
 
 
 
 
1 3.5 
5-7 
6-7 
7 
5.5-7 
7 
6 Colon 
-Right 
-Mid 
-Left 
 
 
Redox potential 
- 415 
- 400 
- 380 
 
1.2.1. Gastrointestinal transit Time: 
Gastric emptying of dosage form is highly variable and depends primarily on 
whether the subject is fed or fasted and on the properties of the dosage form such as size 
and density. The transit times of dosage forms in tract are shown in Table 3. 
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Table 3: Gastrointestinal Transit time of contents: 
Organ Transit Time (hr) 
Stomach 
Small intestine 
Large intestine 
<1(fasting)>3(fed) 
3-4 
20-30 
 
1.3. Pharmaceutical approaches for CTDDS:  
                                                                                          (Akhil guptha et al., 2011) 
Various pharmaceutical approaches that can be exploited for the development of 
colon targeted drug delivery systems are given below: 
Approaches used for site specific drug delivery are  
 Primary approaches for CTDDS: 
 PH sensitive polymer coating drug delivery to colon. 
 Delayed (time controlled release system) release drug delivery to colon. 
 Microbially triggered drug delivery to colon. 
                 i) Prodrug approach for drug delivery to colon. 
                 ii) Azo – polymeric approach for drug delivery to colon                                                                                                                     
                 iii) Polysaccharide based approach for drug delivery to colon. 
 
 
 
 
Colon Targeted Micropellets of  Mebeverine HCl                                                       Introduction 
 
 
Adhiparasakthi College of  Pharmacy, Melmaruvathur. Page 11 
 
 Newly developed approaches for CTDDS: 
 Pressure controlled drug delivery system (PCDCS) 
 CODESTM (a novel colon targeted delivery system) 
 Osmotic controlled drug delivery to colon (OROS – CT) 
 Pulsincap system 
 Port system 
 Time clock system 
 Chronotropic system 
 Colal – Pred system 
 Target technology 
 Ticking capsule 
 Enterion capsule technology 
1.3.1. Primary Approaches: 
1.3.1.1. pH   Dependent Systems: 
The pH-dependent systems exploit the generally accepted view that pH of the 
human GIT increases progressively from the stomach (pH 1-2 which increase to 4 during 
digestion), small intestine (pH 6 - 7) at the site of digestion and it increases to 7-8 in the 
distal ileum. The gamma scintigraphy technique becomes most popular technique to 
investigate the gastrointestinal performance of pharmaceutical formulations. The pH 
sensitive polymers (given in Table 4) which will produce delayed release and also give 
protection from gastric fluids. 
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Table 4: List of Enteric Polymers used in the development of Modified-Release                           
Formulations for Colonic drug Delivery systems 
 
S.No. Enteric Polymers Optimum pH for dissolution 
1 Polyvinyl acetate phthalate (PVAP) 5.0 
2 Cellulose acetate tri melitate (CAT) 5.5 
3 Hydroxypropyl methylcellulose phthalate 
(HPMCP) 
> 5.5 
4 Hydroxy propyl methylcellulose acetate 
succinate (HPMCAS) 
> 6.0 
5 Methacrylie acid copolymer, Type C (Eudragit 
L100-55) 
> 6.0 
6 Methacrylic acid copolymer dispersion 
(Eudragit L30D-55) 
> 5 
7 Methacrylic acid copolymer, Type A > 6.0 
8 (Eudragit®L-100 and Eudragist L12,5) _ 
9 Cellulose acetate phthalate (CAP) (Aquateric) 6.0 
10 Methacrylic acid copolymer, Type B > 7.0 
11 (Eudragist S-100 and Eudragit S12,5) _ 
12 Eudragit FS30D > 7.0 
13 Shellac (MarCoat 125 &125N) 7.0 
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                                      Fig.3:  Chemical structure of Eudragit 
The selected polymers to colon targeting should be able to withstand the pH of the 
stomach and small intestine. Methacrylic acid esters most commonly used polymers for 
colon targeting because they are soluble at above pH 6. The ideal polymer should be able 
to withstand the lower pH of the stomach and of the proximal part of the small intestine 
but able to disintegrate at neutral or shortly alkaline pH of the terminal ileum and 
preferably at ileocecal junction. Eudragit-L and Eudragit S are widely used in the colon 
targeting because Eudragit L is soluble at pH 6 or above and Eudragit S is soluble at pH 7 
or above and the combination of these polymers give the desirable release rates. The 
polymers of this class are insoluble at low PH levels but become increasingly soluble as 
PH rises. The polymers of this class protect the formulation from the acidic PH and 
proximal small intestine, it may start to dissolve in the lower small intestine, and the site 
specificity of formulations can be poor. PH-sensitive hydro gels were prepared for colonic 
delivery of therapeutic peptides, proteins. New pH-sensitive glycopolymers were 
developed by free radical polymerization of Methacrylic acid and 6-hexandiol diacrylate 
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and 6- hexandiol propoxylate diacrylate. Colon targeted drug delivery systems based on 
methacrylic resins has described for insulin, prednisolone, quinolones, salsalazine, 
cyclosporine, beclomethasone dipropionate and naproxen, Khan et al. prepared lactose-
based placebo tablets and coated using various combinations of two methacrylic acid 
polymers, Eudragit L100-55 and Eudragit S100 by spraying from aqueous systems. The 
same coating formulations are then applied on tablets and evaluated for in vitro 
dissolution rates under various conditions. 
1.3.1.2. Time-Dependent Systems: 
1. Time dependent systems are very promising type of drug release systems. The dosage 
forms also applicable to colon targeting dosage forms by prolonging the lag time of about 
5 to 6 hours. 
2. Gastric emptying time varies markedly between subjects or in a manner dependent on 
type and amount of food intake.  
3. Gastrointestinal movement, especially peristalsis or contraction in the stomach would 
result in change in gastrointestinal transit of the drug. 
4. Accelerated transit through different regions of the colon has been observed in patients 
with the IBD, the characinoid syndrome and diarrhea, and the ulcerative colitis. 
  Therefore, time dependent systems are not ideal to deliver drugs to the colon 
specifically for the treatment of colon related diseases. Colon targeting could be achieved 
by incorporating a lag time into formulation equivalent to the mouth to colon transit time. 
The basic principle involved in the system is the release of drug from dosage form should 
be after a predetermined lag time to deliver the drug at the right site of action at right time 
and in the right amount. Enteric coated time-release press coated (ETP) tablets, are 
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composed of three components, a drug containing core tablet (rapid release function), the 
press coated swellable hydrophobic polymer layer (Hydroxy Propyl cellulose layer 
(HPC), time release function) and an enteric coating layer (acid resistance function).The 
tablet does not release the drug in the stomach due to the acid resistance of the outer 
enteric coating layer. After gastric emptying, the enteric coating layer rapidly dissolves 
and the intestinal fluid begins to slowly erode the press coated polymer (HPC) layer. 
When the erosion front reaches the core tablet, rapid drug release occurs since the erosion 
process takes a long time as there is no drug release period (lag phase) after gastric 
emptying. The duration of lag phase is controlled either by the weight or composition of 
the polymer (HPC) layer.  
 
         Fig. 4: Design of enteric coated timed-release press coated tablet (ETP Tablet) 
A nominal lag time of five hours is usually considered sufficient to achieve colon 
targeting. In this method the solid dosage form coated with different sets of polymers and 
the thickness of the outer layer determines the time required disperse in aqueous 
environment Hydroxy Propyl Methyl Cellulose (HPMC) compression coated tablets of 5-
fluorouracil were studied for colon drug delivery that based on time-dependent approach. 
In this, the core tablet was prepared by wet granulation method and then coated with 50% 
of HPMC/lactose coat powder by compression-coating method. Drug release 
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characteristics were evaluated in distilled water by using a Chinese pharmacopoeia 
rotatable basket method. 
1.3.1.3. Micro Flora Activated System: 
  A large number of anaerobic and aerobic bacteria are present the entire length of 
the human GI tract. Over 400 distinct bacterial species have been found, 20- 30% of 
which are of the genus bactericides. The upper region of the GIT has a very small number 
of bacteria and predominantly consists of gram positive facultative bacteria. The rate of 
microbial growth is greatest in the proximal areas because of high concentration of 
energy source. 
Table 5: The human gastro-intestinal flora: 
   
 Stomach Jejunum Ileum Feces 
Total bacterial count 0-103 0-105 103-107 1012-1012 
Anaerobic bacteria 
E.Coli 0-102 0-103 102-106 104-1010 
Strepto cocci 0-103 0-104 102-106 105-1010 
Staphylo cocci 0-102 0-103 102-105 104-107 
Lactobacilli 0-103 0-104 102-105 106-1010 
Fungi 0-102 0-102 102-103 102-106 
Anaerobic bacteria 
Bacteroids Rare 0-102 103-105 1010-1012 
Bifid bacteria Rare 0-103 103-107 108-1012 
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          The metabolic activity of micro flora can be modified by various factors such as 
age, GI disease, and intake of drug and fermentation of dietary residues 
1.3.1.3.1. Prodrug approach: 
A Prodrug is a pharmacologically inactive derivative of a parent compound that 
requires enzymatic transformations in order to release the drug and that has improved 
release properties over the parent compound.  Formulation of Prodrug has improved 
delivery properties over the parent compound. The choice of carrier is largely determined 
by the functional group available on the drugs.There are at least three factors should be 
optimized for the site specific delivery of drugs by using the Prodrug approach. 
1. The Prodrug must to reach the target for the site of action as early as possible, and 
uptake from the site must be fast and essentially perfusion rate limited. 
2. Once the drug reached to the site, Prodrug must be selectively liberated to the 
active drug relative to its conversion at other sites. 
3. Once selectively liberated at the site of action, the active drug must be somewhat 
retained by the tissue. 
  The problem of stability of certain drugs from the adverse environment of the 
upper GIT can be eliminated by Pro drugs formation, which is converted into parent drug 
molecule once it reaches to colon. Enzymes produced by bacterial flora, which are 
responsible for the cleavage of Prodrug, are listed in Table  
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Table 6: Enzymes in Colon: 
S.No. Type Examples 
 
1 
Reducing enzymes Nitroreductase 
Azoreductases 
N-oxide reductase 
Sulphoxide reductase 
Hydrogenase 
 
2 
Hydrolytic enzymes Esterasess 
Acidizes 
Glycosidase 
Glucuronidase 
Sulfites 
     
1.3.1.3.2. Azo-Prodrugs:  
One of the first prodrugs on the market that used colonic enzymatic 
biodegradation as its active principle was sulfasalazine (salazosulfapyridine) and the 
other modern successor products are olsalazine, balsalazine, and ipsaslazine, all of them 
used for the treatment of inflammatory bowel diseases and containing two molecules 
linked by an azo bond. The prodrugs pass the stomach and the small intestine unchanged 
and unabsorbed. Reaching the caecum, they are reduced and cleaved by specific 
azoreductases of the microflora20. During this process of enzymatic decomposition, the 
drug is released in a micro-fine physical state that promotes rapid and extensive 
dispersion, and thus guarantees maximal topical and systemic activity. 
1.3.1.3.3. Polysaccharide based delivery system: 
Use of natural occurring polysaccharides is of attention for drug targeting to coon 
since these polymers of monosaccharide’s are found in abundance, have wide availability 
are inexpensive and are available in a variety of structures with varied properties. They 
can be easily modified chemically and biochemically and are highly stable, nontoxic, 
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hydrophobic and gel forming and in addition biodegradable. These include naturally 
occurring polysaccharides obtained from plant, animal (chytosan, chondiotin sulphate), 
argal (alginates) as microbial origin. These are broken down by colonic micro flora to 
simple saccharides. So these falls into category of “generally regarded as safe” (GRAS) 
polysaccharide based delivery system have outlined in table 7. 
Table 7: List of Natural polymers (Polysaccharide Approach) used in colon specific 
drug delivery 
Polymer Structure Comments 
Guar Gum 
Galactomannan 
polysaccharide (β-1,4 D-mannose, α-1,6 D-
galactose)  having (1-4) linkage 
It has low water 
solubility but hydrates 
and swells in cold 
water forming viscous 
colloidal dispersions 
or solutions. 
Chondroitin 
Sulfate 
 
Mucopolysaccharide consisting of β-1,3 D-
glucuronic acid linked to N-acetyl-D-
galactosamide 
It is readily water 
soluble. So it is used 
with combination of 
nonbiodegradable 
swelling polymers. 
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Pectin 
 
α-1,4 D-galacturonic acid and 1,2 L-rhamnose 
with D-galactose and L-arabinose side chains 
Calcium and Zinc 
crosslinked Pectin 
have more drug 
retention property 
when compared to 
Pectin. 
Amylose 
 
Liner polymer of glucopyranose units (α-1,4 D-
glucose) linked through α–D-(1,4)-linkages 
Amylose is resistant to 
pancreatic amylases. 
Dextran 
 
It consists of α-1,6 D-glucose and α-1,3 D-
glucose units 
Daxtran hydrogels are 
stable in the presence 
of small intestinal 
enzymes 
amyloglucosidase, 
invertase, and 
pancreatin. 
Starch 
 
It consists of amylase and amylopectin 
Starch is hydrolysed 
by several amylolytic 
enzymes in the gut. A 
colon drug delivery 
composition has been 
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described using starch 
capsules to contain the 
drug followed with pH 
sensitive material or 
colonic microbial 
enzyme degradable 
coating. 
Chitosin 
 
Poly (2-amino 2-deoxy D-glucopyranose) in 
which the repeating units are linked by (1-4) β-
bonds 
It dissolves in the 
acidic pH of the 
stomach but swells at 
pH 6.8, so enteric 
coating is required. 
Cyclodextrin 
 
It consists of at least six glucopyranose units 
joined by α- (1-4) linkage 
Cyclodextrins can be 
fermented to small 
saccharides by colonic 
microflora, whereas 
they are only slowly 
hydrolysable in the 
conditions of the upper 
gastrointestinal tract. 
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1.3.2. Newly Developed Approaches for CTDDS: 
1.3.2.1. Pressure Controlled Drug-Delivery Systems: 
It is due to peristalsis, higher pressures are encountered in the colon than in the 
small intestine. Takaya et al. developed pressure controlled colon-delivery capsules using 
ethyl cellulose, which is insoluble in water. In such systems, drug release occurs followed 
by disintegration of a water-insoluble polymer capsule because of pressure in the lumen 
of the colon. The thickness of the ethyl cellulose membrane is an important factor for the 
disintegration of the formulation .The system also depends on capsule size and density. 
Because of re absorption of water from the colon, the viscosity of luminal content is 
greater in the colon than in the small intestine. It is therefore been concluded that drug 
dissolution in the colon could present a problem in relation to colon-specific oral drug 
delivery systems. In pressure controlled ethyl cellulose single unit capsules the drug is in 
a liquid form. Lag times of three to five hours in relation to drug absorption were noted 
when pressure-controlled capsules were administered to humans.  
 
1.3.2.2. Novel Colon Targeted Delivery System (CODESTM): 
CODESTM is a unique CTDDS technology that was designed to avoid the 
inherent problems associated with pH or time dependent systems. CODESTM is a 
combined approach of pH dependent and microbial triggered CTDDS. It has been 
developed by utilizing a unique mechanism involving lactulose, which acts as a trigger 
for site specific drug release in the colon.     
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                   Fig .5:  Schematics of the conceptual design of CODES  
The system consists of a traditional tablet core containing lactulose, which is over 
coated with and acid soluble material, Eudragit E, and then subsequently over coated 
with an enteric material, Eudragit L. The premise of the technology is that the enteric 
coating protects the tablet while it is located in the stomach and then dissolves quickly 
following gastric emptying. The acid soluble material coating then protects the 
preparation as it passes through the alkaline pH of the small intestine. Once the tablet 
arrives in the colon, the bacteria enzymatically degrade the polysaccharide (lactulose) 
into organic acid. This lowers the pH surrounding the system sufficient to affect the 
dissolution of the acid soluble coating and subsequent drug release. 
1.3.2.3. Osmotic Controlled Drug Delivery (OROS-CT): 
The OROS-CT (Alza Corporation) can be used to target the drug locally to the 
colon for the treatment of disease or to achieve systemic absorption that is otherwise 
unattainable .The OROS-CT system can be a single osmotic unit or may incorporate as 
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many as 5-6 push-pull units, each 4 mm in diameter, encapsulated within a hard gelatin 
capsule, . Each bilayer push pull unit contains an osmotic push layer and a drug layer, 
both surrounded by a semi permeable membrane. An orifice is drilled through the 
membrane next to the drug layer. Immediately after the OROS-CT is swallowed, the 
gelatin capsule containing the push-pull units dissolves. Because of its drug-impermeable 
enteric coating, each push-pull unit is prevented from absorbing water in the acidic 
aqueous environment of the stomach, and hence no drug is delivered. As the unit enters 
the small intestine, the coating dissolves in this higher pH environment (pH >7), water 
enters the unit, causing the osmotic push compartment to swell, and concomitantly 
creates a flowable gel in the drug compartment. Swelling of the osmotic push 
compartment forces drug gel out of the orifice at a rate precisely controlled by the rate of 
water transport through the semipermeable membrane. For treating ulcerative colitis, 
each push pull unit is designed with a 3-4 h post gastric delay to prevent drug delivery in 
the small intestine. Drug release begins when the unit reaches the colon. OROS-CT units 
can maintain a constant release rate for up to 24 hours in the colon or can deliver drug 
over a period as short as four hours. Recently, new phase transited systems have come 
which promise to be a good tool for targeting drugs to the colon. Various in vitro / in vivo 
evaluation techniques have been developed and proposed to test the performance and 
stability of CTDDS.  
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           Fig.6: Cross-Section of the OROS colon targeted drug delivery system 
 
These days the basic CTDDS approaches are applied to formulate novel drug 
delivery systems. Such as Multiparticulate systems, Microspheres, Liposomes, 
Microencapsulated particles, Micro pellets etc. 
1.3.2.4. Pulsatile system: 
In recent years considerable attention has been focused on the development of 
pulsatile drug delivery system. Delivery system with pulsatile release pattern has gained 
most popular form of controlled drug delivery system because conventional systems with 
a continuous release are not ideal. Oral controlled drug delivery systems are generally 
used due to convenient dosage form and it also releases drug in constant or variable rates. 
In these system drug release generally occurs within therapeutic window for prolong 
period of time. Hence these systems show sustained release of drug from dosage form.  
Pulsatile release systems are formulated to undergo a lag-time of predetermined span of 
time of no release, followed by a rapid and complete release of loaded drugs. The 
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approach is based on the principle of delaying the time of drug release until the system 
transits from mouth to colon. A lag-time of 5 hours is usually considered sufficient since 
small intestine transit is about 3-4 hours, which is relatively constant and hardly affected 
by the nature of formulation administered. 
                                          
                                                Fig. 7: Enteric coated pulsing cap 
1.3.2.5. Port System: 
The Port system was developed by Therapeutic System Research Laboratory Arm 
Arbor, Michigan, USA, and consists of a capsule coated with a semi permeable 
membrane (Figure 8) inside the capsule was an insoluble plug consisting of osmotically 
active agent and the drug formulation. System shows good in-vivo and in-vitro 
correlation in humans and used to deliver methylphenidate to school age children for the 
treatment of attention deficit hyperactivity disorder (ADHD). 
Colon Targeted Micropellets of  Mebeverine HCl                                                       Introduction 
 
 
Adhiparasakthi College of  Pharmacy, Melmaruvathur. Page 27 
 
 
                                         Fig.8:  Design of PORT system 
1.3.2.6. Time clock: 
  In this, drug releases after a predetermined lag time. The  lag  time  usually  starts  
after  gastric emptying   because  most  of  the  time-controlled formulations  are  enteric  
coated. Drug release from these systems is not pH dependent. 
 
                                             Fig.9:  Design of Time clock system 
1.3.2.7. Chronotropic system: 
These systems are based upon a drug reservoir surrounded with a soluble barrier 
layer that dissolves with time and the drug releases at once after this lag time. 
Chronotropic system consists of a core containing reservoir coated by a hydrophilic 
polymer HPMC. An additional enteric-coated film is given outside this layer to overcome 
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intra subject variability in gastric emptying rates (Figure 10).The lag time and the onset 
of action are controlled by the thickness and the viscosity grade of HPMC. 
 
                                    Fig .10:  Design of Chronotropic system 
 
1.3.2.8. Colol-Pred System: 
COLAL-PRED is a proprietary gastrointestinal product developed by Alizyme for 
the treatment of ulcerative colitis (US). It has arisen from combining Alizyme’s 
properitary colonic drug delivery system, COLAL, with an approved generic steroid 
(Prednisolone sodium Meta sulfo benzoate). It is an effective anti inflammatory treatment 
for UC without the typical side effects of steroids. There are currently no competitor 
products, either on the market or in development, with the same profile of product. A 
‘Safe steroid’ product with the profile of 
COLAL-PRED would represent a significant advance in the management of UC. 
COLALPRED has a coating that is broken down only in the colon, by locally occurring 
bacteria. This leads to topical delivery of prednisolone to the colon without significant 
systemic exposure so minimizing steroid related side effects. 
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1.3.2.9. Targit Technology: 
TARGIT Technology (West Pharmaceutical services) is designed for site-specific 
delivery of drugs in the gastrointestinal (GI) tract and, in particular, targeted release into 
the colonic region. A key area of application is the delivery of therapeutic agents for local 
treatment of lower GI diseases. The technology is based on the application of pH- 
Sensitive coatings onto injection-moulded starch capsules. An extensive body of clinical 
data has been generated showing reliable in vivo performance of the capsules. In Y-
Scintigraphy studies, around 90% of TARGIT Capsules (n=84) delivered their contents 
to the target site of the terminal ileum and colon. TARGIT based products are in active 
clinical development for the treatment of conditions including inflammatory bowel 
diseases. 
 
1.3.2.10. Ticking capsule: 
It is a chronotherapeutic devices employ some electrical means of controlling 
pulsatile drug release coupled with electronic timing. Ticking capsules is divided into 
three compartments; Porous Si-based drug delivery module; Electronic control module 
(e.g. mucontroller) and Battery. (Figure 12) Many human illnesses and their Symptoms 
show a regular (rhythmic) pattern: Hypertension (early morning); arthritics pain (mid 
afternoon); heart attack (early morning + late afternoon and asthma attack (night). It is 
recognizing intake into the body is limed to match the severity of the Symptom. 
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                               Fig.11:  Design of ticking capsule system 
 
1.3.2.11. Enterion capsule Technology: 
The Enterion capsule has recently been developed by Phacton Research, 
Nottingham, UK, for targeted delivery of a wide range of different drug formulations into 
any region of the gut (Fig-12). It is a 32-mm long, round-ended capsule and contains a 
drug reservoir with a volume capacity of approximately 1 ml. The capsule can be loaded 
with either a liquid formulation (e.g. Solution, Suspension) or a particulate formulation 
(e.g., powder, pellets, in sit affects etc.) through an opening 9 mm in diameter, which is 
then sealed by inserting a push-on Cap fitted with a silicone O-ring. The floor of the drug 
reservoir is the piston face, which is held back against a compressed spring by a high 
tensile strength polymer filament. 
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                                        Fig. 12: Design of Enterion capsule 
A radioactive marker is placed inside a separate sealed tracer port to allow real 
time visualization of the capsule location using the imaging technique of gamma 
Scintigraphy. When the capsule reaches the target location in the gastrointestinal tract, 
the contents are actively ejected by the external application of an oscillating magnetic 
field. The frequency of the magnetic field is set in the low MHz region, low enough so 
that there is negligible absorption of the energy by the body tissues but sufficiently high 
enough to induce unable power in a tuned coil antenna embedded in the capsule wall. The 
power induced in the coil by the magnetic field is fed to a tiny heater resistor located 
within a separate sealed electronics compartment inside the capsule. Although the power 
is only a few tenths of a wall, the small size of the heater (less than 1mm3) means that 
heat build up is extremely rapid. The heater resistor is in direct contact with the 
restraining filament, causing it to softer and breaks with the increase in temperature. This 
is turn, releases the spring and driver the piston. The resulting increase in pressure within 
the drug reservoir forces off the O-ring sealed cap and rapidly ejects the drug or drug 
formulation into the surrounding GI fluids. The piston motion is stopped near the end of 
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the capsule, which maintains a seal and presents contact of the internal electronic 
compartments with the GI fluids. The movement of the piston also operates a switch, 
which directs some of the electrical energy away from the heater and uses it to transmit a 
weak radio signal at a precise frequency. Detection of this signal externally confirms that 
the capsule has opened successfully. 
1.3.2.12. Multi particulates: 
Multiparticulate (pellets, non-peariles etc.) are used as drug carriers in pH-
sensitive, time dependent and microbial control systems for colon targeting. 
Multiparticulate systems have several advantages in comparison to the conventional 
single unit for controlled release technology, such as more predictable gastric emptying 
and fewer localized adverse effect than those of single unit tablets or capsules. 
A multi particulate dosage form was prepared to deliver active molecules to 
colonic region, which combines pH dependent and controlled drug release properties. 
This system was constituted by drug loaded cellulose acetate butyrate (CAB). 
Microspheres loaded by an enteric polymer (Eudragit S). Here the enteric coating layer 
prevents the drug release below pH 7. After that CAB microspheres efficiently controlled 
the release of budesonide, which is depended on the polymer concentration in the 
preparation. Azo polymer coated pellets were used for colon-specific drug delivery to 
enhance the absorption of insulin and (Asu1, 7) Eel calcitonin. 
            A multi particulate chitosan dispersed system (CDS) was prepared for colon drug 
delivery and it was composed of the drug reservoir and the drug release-regulating layer, 
which was composed of water insoluble polymer and chitosan powder. The drug 
reservoir was prepared by drug containing multi particulates like Non peariles in the 
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study. In this study the multi particulate CDS was adopted not only for colon specific 
drug delivery but also for sustained drug delivery. 
A Multiparticulate system combining pH sensitive property and specific 
biodegradability was prepared for colon targeted delivery of metronidazole. The 
Multiparticulate system was prepared by coating cross-linked chitosan microspheres 
exploring Eudragit L-100 and S-100 as pH sensitive polymers. The in-vitro drug release 
studies shows that no release of drug at acidic pH and higher drug release were found in 
presence of rat caecal contents indicating susceptibility of chitosan matrix to colonic 
enzymes released from rat caecal contents.  
            High-Amylose corn-starch and Pectin blend micro particles of diclofencac sodium 
for colon-targeted delivery were prepared by spray drying technique. The blending of 
high-amylose corn-starch with pectin improved the encapsulation efficiency and 
decreased the drug dissolution in the gastric condition from pectin based micro particles. 
The drug released in colonic region by the action of pectinase from micro particles. 
It was investigated that the effect of sodium glycocholate as absorption Promoter 
on orally administrated insulin absorption utilizing a colon-targeted delivery system. A 
novel insulin colon-targeted delivery system (Insulin- CODES) contains insulin, lactulose 
as a trigger for colon-specific release, citric acid as a solubilizer of insulin, meglumine as 
a pH adjusting agent and sodium glycocholate as an absorption promoter. 
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1.4. Irritable bowel syndrome (IBS): 
       (Spastic colon; Irritable colon; mucous colitis; Spastic colitis) 
                                                                                 (www.wikipedia.com) 
Irritable bowel syndrome (IBS) is a disorder that leads to abdominal pain and 
cramping, changes in bowel movements, and other symptoms.IBS is not the same as 
inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. 
In IBS, the structure of the bowel is not abnormal. 
                                
Fig.13:  Showing muscle contraction of the large bowel in a case of irritable bowel 
syndrome. 
 
Classification: 
 IBS can be classified as either diarrhea-predominant (IBS-D), constipation-
predominant (IBS-C) or IBS with alternating stool pattern (IBS-A or pain-predominant). 
In some individuals, IBS may have an acute onset and develop after an infectious illness 
characterized by two or more of the following: fever, vomiting, diarrhea, or positive stool 
culture. This post-infective syndrome has consequently been termed "post-infectious 
IBS" (IBS-PI) 
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 Symptoms of IBS: 
 The primary symptoms of IBS are abdominal pain or discomfort in association 
with frequent diarrhea or constipation, a change in bowel habits. There may also be 
urgency for bowel movements, a feeling of incomplete evacuation (tenesmus), bloating 
or abdominal distention. In some cases, the symptoms are relieved by bowel movements.  
People with IBS, more commonly than others, have gastro esophageal reflux,  symptoms 
relating  to  the genitourinary  system, chronic fatigue, fibromyalgia,  headache, backache 
and psychiatric symptoms such as depression  and anxiety.  Some studies indicate that up 
to 60% of persons with IBS also have a psychological disorder, typically anxiety or 
depression.  
 
 Treatment and Medications for IBS: 
 Medications 
Medications may consist of stool softeners and laxatives in constipation-
predominant IBS, and antidiarrheals (e.g., opiate, opioid,  or opioid  analogs such 
as loperamide, codeine, diphenoxylate) in diarrhea-predominant IBS for mild symptoms 
and stronger opiates such as morphine and oxycodone for severe cases. Drugs 
affecting serotonin (5-HT) in the intestines can  help  reduce symptoms. Serotonins 
stimulate the gut motility and so agonists can help constipation-predominate irritable 
bowel, while antagonists can help diarrhea-predominant irritable bowel. 
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 Laxatives: 
For patients who do not adequately respond to dietary fiber, 
osmotic laxatives such as polyethylene glycol, sorbitol, and lactulose can help avoid 
"cathartic colon" which has been associated with stimulant laxatives. Among the osmotic 
laxatives, 17–26 grams/day of polyethylene glycol (PEG) has been well studied. 
Lubiprostone (Amitiza) is a gastrointestinal agent used for the treatment 
of idiopathic chronic constipation and constipation-predominant IBS. It is well tolerated 
in adults, including elderly patients. As of July 20, 2006, Lubiprostone had not been 
studied in pediatric patients. Lubiprostone is a bicyclic fatty acid (prostaglandin E1 
derivative) that acts by specifically activating ClC-2 chloride channels on the apical 
aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These 
secretions soften the stool, increase motility, and promote spontaneous bowel movements 
(SBM). Unlike many laxative products, Lubiprostone does not show signs of tolerance, 
dependency, or altered serum electrolyte concentration. 
 Antispasmodics: 
 These of antispasmodic drugs (e.g., anticholinergics  such as hyoscyamine  or 
 dicyclomine) may help patients, especially those with cramps or diarrhea. A meta-
analysis by the Cochrane Collaboration concludes that if seven patients are treated with 
antispasmodics, one patient will benefit. Antispasmodics can be divided in two groups: 
neurotropics and musculotropics. 
 Neurotropics, such as a phenobarbital like Donnatal or atropine, act at the nerve 
fibre of the parasympathicus but also affect other nerves and have side effects. 
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 Musculotropics such as mebeverine act directly at the smooth muscle of the 
gastrointestinal tract, relieving spasm without affecting normal gut motility. Since this 
action is not mediated by the autonomic nervous system, the usual anticholinergic side 
effects are absent. 
CLASSIFICATION OF ANTISPASMODICS  
Antimuscarinics (Anti-cholinergic):  
            1. Dicyclomine  
            2. Atropine  
            3. Hyoscine  
4. Propantheline  
Mebeverine and related compounds:  
Alverine, Drotaverine, Penavarium  
 Tricyclic antidepressants: 
There is strong evidence that low doses of tricyclic antidepressants can be 
effective for irritable bowel syndrome. However, there is less robust evidence as to the 
effectiveness of other antidepressant classes such as SSRIs (Selective serotonin reuptake 
inhibitors).  
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1.5. Pelletization:                                                     (www.pharmainfo.net) 
Pellets: Pellets can be defined as small, free flowing, spherical or semi-spherical solid 
units, typically from about 0.5 mm to 1.5 mm, and intended usually for oral 
Administration, manufactured by the agglomerates of fine powders or granules of bulk 
drugs and Excipients using appropriate processing equipment. Pellets can be prepared by 
many methods, the compaction and drug-layering being the most widely used today. 
1. Regardless of which manufacturing process is used, pellets have to meet the following 
requirements. They should be near spherical and have a smooth surface; both considered 
optimum characteristics for subsequent film coating. 
2. The particle size range should be as narrow as possible. The optimum size of pellets 
for pharmaceutical use is considered to be between 600 and 1000mm. 
3. The pellets should contain as much as possible of the active ingredient to keep the size 
of the final dosage form within reasonable limits. They should be near spherical and have 
a smooth surface; both considered optimum characteristics for subsequent film coating. 
4. The particle size range should be as narrow as possible. The optimum size of pellets 
for pharmaceutical use is considered to be between 600 and 1000mm. 
5. The pellets should contain as much as possible of the active ingredient to keep the size 
of the final dosage form within reasonable limits. 
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6. Regardless of which manufacturing process is used, pellets have to meet the following 
requirements. They should be near spherical and have a smooth surface; both considered 
optimum characteristics for subsequent film coating. 
1.6. Significance of Pellets: 
Pellets may have varied applications in varied industries. It just requires an 
innovative bend to use it to derive maximum profitability. The smooth surface & the 
uniform size of the pellets allow uniform coating not only for each pellet but also from 
batch to batch. 
Highlighted below are some of the few instances where smooth surfaced uniform 
pellets are being successfully used:   
1. Improved appearance of the products. Coating of pellets can be done with different 
drugs to enable a controlled  releaserate. 
2. In case of immediate Release Products larger surface area of pellets enables better 
distribution. 
3. Chemically incompatible products can be formed into pellets & delivered in a single 
dose   byencapsulatingthem. 
4. In the chemical industries it is used to avoid powder dusting.   
5. Pellets ensure improved flow properties, and flexibility in formulation development 
and  manufacture. 
6. Coating material may be colored with a dye material so that the beads of different 
coating thickness will be darker in color and distinguishable from those having few coats. 
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1.7. Theory of pellet formation: 
In order to judiciously select and optimize any pelletization/granulation process, it 
is important to understand the fundamental mechanisms of granule formation and growth. 
Different theories have been postulated related to the mechanism of formation and 
growth of pellets. As the conventional granulation, the most thoroughly studied, most 
classified pelletization process, which involves a rotating drum, a pan or a disc, has been 
divided into three consecutive regions: nucleation, transition and ball growth. However, 
based on the experiments on the mechanism of pellet formation and growth, the 
following steps were proposed: nucleation, coalescence, layering and abrasion transfer. 
1.8. Methods of Preparing Pellets: 
Compaction and drug layering are the most widely used pelletization techniques 
in pharmaceutical industry. Of the compaction techniques, extrusion and spheronization 
is the most popular method. Recently, however, melt pelletization has been used 
frequently in making compaction pellets using a different type of equipment, e.g. a high-
shear mixer. Other pelletization methods such as globulation, balling and Compression 
are also used in development of pharmaceutical pellets although in a limited scale. 
1.8.1. Powder layering: 
Powder layering involves the deposition of successive layers of dry powders of 
drugs and excipients on preformed nuclei or cores with the help of binding liquids. As 
powder layering involves simultaneous application of binding agents and dry powders, 
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hence it requires specialized equipments like spheronizer. The primary requirement in 
this process is that the product container should be solid walls with no perforation to 
avoid powder lose beneath the product chute before the powder is picked off by the wet 
mass of pellets that is being layered. 
1.8.2. Solution / suspension layering: 
Solution/suspension layering involves the deposition of successive layers of 
solution or suspensions of drug substances and binder over the starter/non-pareil seeds, 
which is an inert material or crystals/granules of the same drug. In fact the coating 
process involved in general is applicable to solution or suspension layering technology. 
Consequently conventional coating pans, fluidized beds, centrifugal granulators, wurster 
coaters have been used successively to manufacture pellets by this method. The 
efficiency of the process and the quality of the pellets produced are in part related to the 
type of equipment used. 
1.8.3. Pelletization by Extrusion and Speronzation:  
The process involves first making of extrudes from the powder material and then 
converting extrudes into beads using the spheronizer. The powder material could be any 
kind of powder (drug powder, ayurvedic powder, food ingredient powder, detergent 
powder, nuclear powder etc), beads as fine as 0.6mm can be made. 
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1.9. Other Pelletization Methods: 
         Other pelletization methods such as globulation, cryopelletization, balling and 
compression are also used, although a limited scale in the preparation of pharmaceutical 
pellets. 
Globulation or droplet formation consist two related processes, spray drying and spray 
congealing. 
Spray drying: 
It is the process in which drugs in the suspension or solution without excipients 
are sprayed in to a hot stream to produce dry and more spherical particles. This process is 
commonly used for improving the dissolution rates; hence bioavailability of poorly 
soluble drugs. 
Spray congealing: 
It is the process in which a drug is allowed to melt, disperse or dissolve in hot 
melts of gums, waxes or fatty acids, and is sprayed into an air chamber where the 
temperature is kept below the melting point of the formulation components, to produce 
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spherical congealed pellets. Both immediate and controlled release pellets can be 
prepared in this process depending on the physiochemical properties of the ingredients 
and other formulation variables. 
Cryopelletization: 
It is a process in which the liquid formulation is converted in to solid spherical 
particles or pellets in the presence of liquid nitrogen as fixing medium. The shape 
depends up on the distance the droplet travel before contacting liquid nitrogen. 
Compression: 
It is one type of compaction technique for preparing pellets. Compacting mixtures 
or blends of active ingredients and excipients under pressure prepare pellets of definite 
sizes and shapes. The formulation and process variables controlling the quality of pellets 
prepared are similar to those used in tablets manufacturing. 
Balling:  
It is the pelletization process in which pellets are formed by a continuous rolling 
and tumbling motion in pans, discs, drums or mixtures. The process consists of 
conversion of finely divided particles in to spherical particles upon the addition of 
appropriate amounts of liquid. 
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1.10. Enteric coatings: 
Enteric coatings are those which remain intact in the stomach, but will dissolve 
and release the contents once it reaches the small intestine. Their prime intension is to 
delay the release of drugs which are inactivated by the stomach contents or may cause 
nausea or bleeding by irritation of gastric mucosa. 
Cracking of the film either during application or on storage will result in a loss of 
enteric properties. Therefore, consideration must be given to the mechanical properties of 
the applied film. Cracking problems can be effectively overcome by plasticization. 
Plasticizer can also be used to reduce the permeability of the polymer films to water 
vapor. The choice of suitable Plasticizer is restricted to non-water soluble materials 
because these are likely to be most effective. 
An evaluation is made of the solubility parameters of species together with an 
assessment of the intrinsic viscosity of dilute solutions of the polymer on the plasticizers. 
This determines the maximum interaction between polymer and Plasticizer, and indicates 
which Plasticizer is likely to be most effective. 
Important reasons for enteric coating are as follows: 
-To protect acid-liable drugs from the gastric fluid 
- to protect gastric distress or nausea due to irritation from drug 
- To deliver drugs intended for local action in the intestines. 
- To deliver drug that are optimally absorbed in the small intestine to their primary 
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absorption   site in their most concentrated form. 
-To provide a delayed release component to repeat actions. 
-Protect the drugs from harmful effect of the gastric contents; some of the drugs are 
prone to be hydrolyzed in acid media (E.g. Esomeprazole, omeprazole, pantaprazole) 
Enteric coating materials: 
Enteric coatings work because they are selectively insoluble substances they 
won't dissolve in the acidic juices of the stomach, but they will when they reach the 
higher pH of the small intestine. 
Most enteric coatings won't dissolve in solutions with a pH lower than 5.5. Commonly-
used enteric coatings may be made from: 
Methacrylic acid copolymers 
Cellulose acetate (and its succinate and phthalate version) 
Polymethacrylic acid/acrylic acid copolymer 
Hydroxypropyl methyl cellulose phthalate 
Poly vinyl acetate phthalate  
Ethyl cellulose phthalate 
Cellulose acetate tetra hydrophtalate 
Acrylic resin 
Shellac 
The most extensively used polymers are CAP, PVAP. The most recently used 
polymers are HPMCP, Methacrylic acid copolymers. 
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Cellulose Acetate Phthalate (CAP): 
Effective enteric coating, it only dissolves above pH 6 and may delay drug release 
longer than desired. It is permeable to moisture and simulated gastric fluid in comparison 
with other enteric polymers and it is susceptible to hydrolytic breakdown on storage. 
Poly Vinyl Acetate Phthalate (PVAP): 
Less permeable to moisture and simulated gastric juice, it is more stable to 
hydrolysis on storage. Enteric dosage forms coated with PVAP disintegrates at pH 5 
Hydroxy Propyl Methyl Cellulose Phthalate (HPMCP): 
It is available in two grades HP50 and HP55, HP55 solutions are more viscous 
than HP50, HP50 disintegrates at pH5 and HP55 disintegrates at pH5.5.It has stability 
similar to that of PVAP and dissolves in the same pH range. The advantage is that it does 
not require Plasticizer. 
Methacrylic acid copolymers: 
Two grades are available A and B which differs in the ratio of free carboxyl to 
ester groups therefore:  
Type A has a ratio of 1:1 and disintegrates at pH 6 
Type B has a ratio of 1:2 and disintegrates at pH 7. 
Available under the trade names Eudragit L and S correspond to NF types A & B. 
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1.11. Coating Equipments: 
Most of the coating processes use one of three general types of equipments. 
1. The standard Coating pan 
2. The Perforated Coating pan 
3. The Fluidized bed coater 
1.11.1. Conventional pan system: 
The standard coating pan system consists of a circular metal pan mounted 
somewhat angularly on a stand, the pan is rotated on its horizontal axis by a motor, the 
hot air is directed into the pan and onto the bed surface, and is exhausted by means of 
ducts positioned through the front of the pan .Coating solutions are applied by spraying 
the material on the bed surface. 
1.11.2. The Perforated Coating pan: 
Neocota is an automatic coating system for tablets and pellets. Neocota is a 
completely updated automatic coating system having a batch capacity of 500 g to 1 kg. 
This model efficiently carries out the following operations: Aqueous film coating of 
tablets/pellets; Non-aqueous organic solvent based film coating of tablets/pellets; and 
enteric film coating of tablets/pellets. 
The basic units of the system are: Coating pan has perforations along its 
cylindrical portion. It is driven by a variable speed drive with a flame-proof motor. 
Supply of hot air and exhaust of drying air are arranged to facilitate the coating system 
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through stainless steel plenums positioned on both sides of the perforated coating pan. 
The pan is enclosed in a cylindrical airtight housing provided with a suitable door and 
front glass window.This housing of pan with drive is a stainless steel cabinet 
accommodating the gearbox, AC variable drive, power panel, hot air unit, ex-haust unit 
and an air fitter. 
Liquid spray system is complete with stainless steel liquid storage vessel, variable 
flow-rate liquid dosing pump, automatic spray gun, and inter-connecting flexible hoses. 
1.11.3. The Fluidized bed coater: 
The Fluid Bed Technology offers a very efficient coating technique. The major 
advantage of the Fluid Bed Systems is that it is as per GMP standards it is a closed 
system. The second advantage of the Fluid Bed Systems is that not only coating but 
granulation and pellet formation is also possible in the same machine. 
  Fluidized bed coating is a process that takes place inside a fluidized bed whereby 
a coat is introduced to cover the intended object in order to protect it or modify its 
behavior. Particulate coating is a form of fluidized bed coating involving the coating of 
solid Particles inside the bed. In the process, a layer is deposited onto the surface of 
fluidized solid particles by spraying with a solution of the coating material. The fluidizing 
gas is also use to dry the deposited solution to form a coat on the surface of the particle. 
There is considerable diversity in methods of using fluidized bed technology. For e.g. 
liquids can be applied to fluidized particles in a variety of ways, including top, bottom 
and tangential spraying. For a given product, each method can offer markedly different 
finished product characteristics. Fluidized beds are used for coating because of their high 
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energy- and mass transfer. Fluidized beds for film coating can be divided into three 
groups 
¨     Top-spray,  
¨     Tangential-spray 
¨     Bottom-spray equipment. 
Top spray: 
The expansion chamber is lengthened to allow powder to remain fluidized longer 
and to move with a higher velocity, so that agglomeration is minimized The expansion 
chamber is conically shaped to allow uniform deceleration of air stream .The filter 
housing is larger and designed to shake the fines back into the bed interrupting 
fluidization.This reduces egglomeration endencies. 
  The nozzle is positioned low in the expansion chamber so that coating material 
impinge on the fluidized particle a short distance from the nozzle; this reduces droplet 
spray drying and provides for longer subsequent drying of the coated particles. The top 
spray coater has been used to apply aqueous and organic solvent based film coatings, 
controlled release coatings. 
Bottom spray coating: (wurster process) 
The wurster machine employs a cylindrical product container with a perforated 
plate. Inside the container is a second cylinder (coating partition) with is raised slightly 
above the perforated plate, centered in the plate below this partition is a spray nozzle used 
to dispense the coating solution. The perforated plated is designed with large holes in the 
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area under the coating partition and smaller holes in the remainder of the plate, except for 
one ring of large holes at the perimeter. The design allows the substrate particles to be 
pneumatically transported upward through the coating partition, and downward outside 
this partition. Material passing through coating partition receives a layer of coating 
material, dries in the expansion chamber, and falls back in a semi fluidized state. Material 
circulates rapidly in this fashion and receives layer of coating material, dries in the 
expansion chamber, and falls back in a semi fluidized state material circulates rapidly in 
this fashion and receives a layer of coating on each pass through the coating partition. 
The ring of large holes on the periphery of perforated plate prevents the accumulation of 
material at the container wall.  
                       Table 8: Parameters Used in Bottom Spray Equipment: 
Inlet temperature 38-42ºC 
Product temperature 32-36ºC 
Exhaust temperature 32-38ºC 
Spray rate 8-12mg/min 
Peristaltic pump 12-18 rpm 
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2. LITERATURE SURVEY 
 
2.1. Literature Review: 
Abdullah GZ., et al. (2010): Mebeverine HCl is a water soluble drug commonly used to 
treat irritable bowel syndrome by acting directly on the smooth muscles of the colon. 
This work was aimed at the formulation and in vitro evaluation of a colon-targeted drug 
delivery system containing mebeverine HCl. Matrix tablets were prepared using ethyl 
cellulose (EC), Eudragit RL 100 either solely or in Combination by wet granulation 
technique. Dissolution was carried out in 0.1 N HCl for 2h followedby pH 6.8 phosphate 
buffer for eight hours. Uncoated forms released more than 5% drug in 0.1 N HCl 
therefore, Eudragit L100 was used as a coat. The results indicated very slow release 
profile. As a result, single retardant was used to prepare the matrix and coated by 
Eudragit L 100. The matrix containing 7% Eudragit RL 100 and 6% of binder was 
subjected to further studies to assess the effect of different coats (Eudragit L 100-55 and 
cellulose acetate phthalate) and different binders (pectin and sodium alginate) on the 
release profile. Eudragit L 100 and pectin were the best coating agent and binder, 
respectively. The final formula was stable and it can be concluded that the prepared 
system has the potential to deliver mebeverine HCl in vivo to the colon. 
Zhongguo Zhong Yao Za Zhi (2006): Shuxiong micropellets were prepared by using a 
centrifugal granulator. The formulation composition and process factors were optimized 
investigated by adopting several indices such as size distribution, repose angle, bulk 
density and friability as indexes. 
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Prabakaran L., et al. (2006): The aim of the investigation is to improve the dissolution, 
wettability, and Micromeritic behavior of domperidone, a dopamine antagonist, used in 
the Treatment of nausea and vomiting. Micropelletization technique, a possible Approach 
for ensuring maximum dissolution with enhanced wettability, and uniform Pellet size 
almost spherical so as to achieve the smooth gastric transit of drug have been estimated. 
Micro pellets were prepared utilizing solvent diffusion Technique and all the process 
parameters such as solvent-non-solvent ratio, Stirring speed, temperature, and effect of 
aggregating agent on the micropellets. Formulations have been optimized. The addition 
of an aggregating agent (10%v/v of isopropyl alcohol) improved the uniform micropellets 
formation and the method was Reproducible. The micromeritic properties such as size 
distribution, surface Property (using Scalar-USB digital photomicroscope), pack ability, 
and flow ability of the formulated micropellets were characterized. Fourier transforms 
infrared Spectroscopy (FTIR) and Differential scanning calorimetric (DSC) analysis were 
performed to explain the results. Formulated micropellets showed clear and highly 
improved in vivo dissolution behavior, probably due to high wettability. The micro 
pelletized drug was stable at room temperature, 25 degrees C/60% relative humidity 
(RH), and 45 degrees C/70% RH, after 12 weeks. 
Tayade PT., et al. (2004): Ibuprofen-gelatin micropellets were prepared by the cross-
linking technique using formaldehyde. Spherical micropellets having an entrapment 
efficiency of 65% to 85% were obtained. The effect of core to coat ratio, speed of 
agitation, temperature, and volume of oil phase was studied with respect to entrapment 
efficiency, micro pellet size, and surface characteristics. Fourier transform infrared 
spectroscopy and differential scanning calorimetric analysis confirmed the absence of any 
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drug-polymer interaction. X-ray diffraction patterns showed that there is a decrease in 
crystallinity of the drug. The micromeritic properties of micropellets were found to be 
slightly changed by changing various processing parameters to give micropellets of good 
flow property. The in vitro release profile could be altered significantly by changing 
various processing parameters to give a controlled release of drug from the micropellets. 
The stability studies of the drug-loaded micropellets showed that the drug was stable at 
storage conditions of room temperature, 37 degrees C, 25 degrees /60% relative humidity 
(RH) and 45 degrees /60% RH, for 12 weeks. 
Mallick S., et al. (2002): Flurbiprofen loaded ethyl cellulose micropellets with different 
drug loading were prepared by a quasi-emulsion solvent diffusion technique. 
Encapsulation parameters of micropellets such as actual drug loading, drug encapsulation 
efficiency (DEE) and loss of coating polymer (LCP) were determined. Actual drug 
loading was increased with the increased initial drug loading whereas encapsulation 
efficiency decreased with the increase of actual drug loading. Invitro drug release profiles 
of these micropellets were evaluated in distilled water (DW) and also in phosphate buffer 
solution (PBS) to indicate pH dependency release rates. All the batches of micropellets 
released about 35-59% in DW and 89-97% in PBS during the period of 8 h and the burst 
effect of about 50-75% in the first 1.5 h was seen only in PBS. The mechanism of release 
kinetics was evaluated by fitting the release data to the zero order, first order, Higuchi, 
Baker-Lonsdale and Pappas equations and also to the differential forms of zero order, 
first order and Higuchi model. Adequate fitting of release data was found with first order, 
Higuchi and Pappas models and hence these models were selected for F-test statistics for 
ascertaining the mechanism of drug release. Higuchi model of drug release in DW and 
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PBS of all the formulations was ruled out due to its significantly different F-value with 
other models. Thus, mechanism of release of flurbiprofen from ethyl cellulose 
micropellets may be explained by the diffusional exponent model of Pappas et al. as 
ascertained by F-test statistics rather than the same, based on some other diffusional 
models even though they have shown good correlation. 
Baidya S., et al. (1999): The objective of the present investigation was to prepare 
nitrofurantoin Micropellets coated with a combination of Eudragit RS 100 and Eudragit 
RL100 Taken in varying ratios to achieve a sustained nitrofurantoin serum and urinary 
level over a prolonged period of time without any side effect. The method adopted was 
phase separation coacervation induced by non-solvent addition. The physical nature of 
the coating film was improved by a protective colloid, polyisobutylene (0% to 3% w/w). 
The optimized formulations were extensively evaluated for particle size analysis, 
Scanning Electron Microscopy, stability studies and finally in vitro and in vivo release 
studies and their statistical evaluation and correlation. 
Bedi S., et al. (1999): Nitrofurantoin, a synthetic bactericidal drug, was encapsulated 
with Eudragit RS 100 polymer by a coacervation phase separation technique using 
variable proportions of polyisobutylene (0% to 3%) as a protective colloid. The 
micropellets were evaluated by scanning electron microscopy (SEM), particle size 
distribution, wall thickness, and loss of wall polymer was determined. The invitro release 
experiments were carried out over the entire pH range of the Gastrointestinal tract, the 
data obtained from the dissolution profiles were compared in the light of different kinetic 
models and the regression coefficients were compared. The in vivo studies were 
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performed on female human volunteers. A linear correlation was obtained from in vitro-
in vivo studies. 
Roy S., et al. (1989): A controlled-release dosage form was manufactured by dispersing 
ethyl cellulosesol in acetone into a medium of mineral oil. Dapsone was used as the 
model drug. The powdered drug was dispersed in the ethyl cellulose sol, and the 
formulation variables affecting the production of the discrete and spherical micropellets 
and their size distribution were investigated. The percentage of SPAN 80 in the 
formulation affected the yield and physical properties of the micropellets. The in vitro 
drug release followed first-order diffusion-controlled dissolution. More than 85% of the 
drug was released over 5 hr for all formulation batches, with delayed release over the 
drug dissolution profile. 
Sahoo SK., et al. (2008): In the present study aceclofenac-gelatine micropellets were 
prepared by the cross linking technique using glutaraldehyde as cross linking  agent and 
characterized by X-ray diffractometry, DSC and SEM. The effect of drug: polymer ratio, 
temperature of oil phase, amount if glutaraldehyde and stirring time was studied with 
respect to entrapment efficiency, micro pellet size and drug release characteristics. 
Spherical micropellets having entrapment efficiency of 57% to 97% were obtained.DSC 
analysis conformed the obscene of drug –polymer interations.The micromeritic studies of 
micropellets show improved flow property. The entrapment efficiency, micro pellet size 
and drug release profile was altered significantly by changing various processing 
parameters. 
Simratha bedi., et al. (1999): The purpose of this study was to design to evaluate a drug 
delivery system of nitrofurantoin to control urinary tract infections by achieving a 
Colon Targeted Micropellets of Mebeverine HCl                                  Lliterature survey 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 56 
 
sustained nitrofurantoin serum and urinary level over a prolonged period of time but 
without the concomitant side effects. Ethyl cellulose multiparticulate micropellets 
containing nitrofurantoin were prepared by using emulsification /solvent evaporation 
technique. The optimized formulation were extensively evaluated using I.R. 
Spectroscopy, particle size analysis, SEM, stability studies and finally invitro and invivo 
release rate studies. No drug polymer interaction could be detected. The release of drug 
more or less followed zero order, first order higuchi and binominal model equation. The 
invitro release studies were monitored over the entire pHrange of GIT fluid. A linear 
correlation was obtained in the in vitro-in vivo studies. 
Mandal M., et al. (1997): Micropellets of pentazocine hydrochloride were fabricated by 
the emulsion solvent evaporation method using different combinations of ethyl cellulose 
and Eudragit RL100. The polymer combinations, drug load, and pHof the dissolution 
medium were found to extert important effects on drug release profile. Release kinetics 
also showed a heterogeneous pattern. 
Laila Fatima, et al. (2006): To achieve successful colon targeted drug delivery, a drug 
needs to be protected from degradation, release and/ or absorption in the upper portion of 
the GI tract and then ensure abrupt or controlled release in the proximal colon. The 
review is aimed at understanding recent advancements made in multiparticulate system 
for colon specific delivery of medicaments. 
Libo Yang, et al. (2002): The necessity and advantages of colon-specific drug delivery 
systems have been well recognized and documented. In the past, the primary approaches 
to obtain colon-specific delivery achieved limited success and included prodrugs, pH and 
time-depending systems, and microflora-activated systems. 
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Khan M.S., et al. (2010): The purpose of this research was to develop and evaluate 
multiparticulates of alginate and chitosan hydrogel beads exploiting pH sensitive property 
for colon-targeted delivery of theophylline. Alginate and chitosan beads were prepared by 
ionotropic gelation method followed by enteric coating with Eudragit S100. All 
formulations were evaluated for particle size, encapsulation efficiency, swellability and in 
vitro drug release. In vitrodissolution studies performed following pH progression 
method demonstrated that the drug release from coated beads depends on coat weights 
applied and pH of dissolution media. Mechanism of drug release was found to be 
swelling and erosion-dependent. The studies showed that formulated alginate and 
chitosan beads can be used effectively for the delivery of drug to colon and a coat weight 
of 20% weight gain was sufficient to impart an excellent gastro resistant property to the 
beads for effective release of drug at higher pH values. 
Varshosza J., et al. (2009): The objective of this study was to develop piroxicam enteric 
coated pellets using nonpareil seeds by powder layering technique to minimize its 
gastrointestinal adverse effects. Inert seeds were prepared by incorporating sugar, Avicel 
PH 101 and lactose. The obtained cores were then treated by PVP 10 w/v % solution 
using centrifugal granulator (CF-granulator) and then coated with micronized piroxicam 
using HPMC solution (8% w/v) as binder. The piroxicam pellets were finally coated with 
different polymers (Eudragit L30D-55, Eudragit L100, Eudragit NE30D, Acryleze, or 
mixture of Eudragits L30D-55 and NE30D) and plasticizers (triethyl citrate and 
polyethylene glycol 6000). Results showed that Eudragit L30D-55 with 3% weight gain 
accompanied with TEC produced suitable enteric coated pellets. 
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Singh S.K., et al (2009): Pellets can be prepared by many methods, the compaction and 
drug-layering being the most widely used today1. The study was undertaken with an aim 
to develop delayed release micropellets dosage form for Lansoprazole which is a 
benzimidazole anti ulcer agent and is one of the most widely used drugs for treating mild 
and severe ulcers. The approach of the present study was to make a comparative 
evaluation among these polymers and excipients and to assess the effect of 
physicochemical nature of the active ingredients on the drug release profile. The 
prototype formulation of micro pellets were prepared using the fluid bed coater (FBC) 
with the air pressure 2.0 bar and the spray rate 10-15ml/min. Temperature of bed is 
varied from 35°C to 50°C and inlet temperature is varied from 50°C to 70°C and the 
effect of various parameter were observed such as air pressure, inlet and outlet 
temperature of FBC, it is observed that at high pressure the pellets are breaking. For bed 
and inlet temperature it is observed that at low temperature lumps are occurring in the 
formulation and at 2.0 bar air pressure, inlet temperature 60°C and bed temperature of 
40°C is reliable for solution flow rate 10-15ml/min. Concerning results of prototype 
preparation of Lansoprazole the micro pellets were prepared using HPMC E5 polymer as 
release retardant in three different concentration i.e. 40%, 50%, 60% with three different 
concentration 8%, 10%, 12% of NaOH and Acrycoat L30D solution was used for enteric 
coating. Formulated micro pellets showed delayed in vitro dissolution behavior, probably 
due to optimized concentration of polymer. The micro pellets drug was stable at room 
temperature, 25°C/60% RH, 30°C/65% RH and 40°C/75% RH as per ICH guidelines, 
after 3 months. 
 
Colon Targeted Micropellets of Mebeverine HCl                                  Lliterature survey 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 59 
 
                                                      2.2. DRUG PROFILE 
(Indian Pharmacopoeia, 2007)                             
(http://en.wikipedia.org/wiki/Mebeverinehttp://en.wikipedia.org/wiki/Colofac) 
MEBEVERINE HYDROCHLORIDE 
Mebeverine Hydrochloride is an anti-spasmodic drug given orally and topically 
(rectal route) for the treatment of irritable bowel disease. Mebeverine is also known as                                                                                                                   
4-(ethyl [1-(4-methoxyphenyl) propan-2-yl] amino) butyl 3, 4-dimethoxybenzoate.                                    
Molecular structure: 
 
.HCl 
 
Empirical formula : C25H35NO5 
 Mol. Weight  : 429.56 gm/mol 
Category  : Anti-spasmodic drug 
CAS. No.  : 2753-45-9 
Physical state  : White or Almost white crystalline powder 
Melting point  : 129-131˚C. 
Odour   : odorless or with a slight characteristic odour 
Solubility : Freely soluble in ethanol (96%), very soluble in water, insoluble 
in ether. 
Half life  : The mean elimination half life is 2.5 hours. 
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Pharmacology:                                  (From Wikipedia, the free encyclopedia,) 
a. Mode of action: 
Mebeverine is an anti muscarinic. Mebeverine belongs to a group of compounds 
called  musculotropic antispasmodics.  These compounds act directly on the gut muscles 
at the cellular level to relax them. Mebeverine is also an inhibitor of calcium-depot 
replenishment. Therefore, mebeverine has dual mode of action which normalizes the 
small bowel motility. 
b. Pharmacokinetic parameter: 
The plasma half-life of Mebeverine is reported to be about 2.5 hours; it is 60-75% 
bound to plasma proteins and peak plasma concentration will produce within 1-3hours.  
c. Indications: 
 Spastic functional disturbances of the colon 
 Irritable bowel syndrome in its primary form, irritable bowel syndrome associated 
with organic lesions of the gastrointestinal tract such as; diverticulosis and 
diverticulitis, regional enteritis, disease of the gall bladder and gall ducts, gastric 
and duodenal ulcers, dysentery, and aspecific or specific inflammation of the 
digestive tract. 
 Mebeverine should be taken 20 minutes before meals. 
d. Uses: 
 Mebeverine is used to treat a number of problems. 
 It is a direct relaxant of gut (intestinal) muscle, and is sometimes known as an          
antispasmodic drug. 
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 It is used to relax the muscles of the intestine and to treat symptoms of irritable 
bowel syndrome and related conditions. 
 In general this drug is used to manage the symptoms of irritable bowelsyndrome, 
a common intestinal condition which causes spasm and pain in the intestine, 
aswellas stomachpain,persistent diarrhoea (sometimes alternating with periods 
of constipation) and wind (flatulence). 
 Benefits of being on this drug include reducing the painful and troublesome 
symptoms of irritable bowel syndrome. 
Listed below are the typical uses of mebeverine. 
 Relief from the symptoms of irritable bowel syndrome as well as other conditions 
usually included in this grouping, such as chronic irritable colon, spastic 
constipation, mucous colitis and spastic colitis. 
 On occasion your doctor may prescribe this medicine to treat a condition not on 
the above list. Such conditions are listed below. 
e. Adverse Effects: 
 reactions consisted of urticariaor maculopapular rash, sometimes accompanied 
by fever, polyarthritis, thrombopenia or angioedema 
f. Contraindication: 
  Mebeverine is contraindicated in cases with  
 Paralytic ileus (lack of bowel movements, leading to blockage of the gut). 
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 Any bleeding disorders (especially bleeding from the gut), severe constipation, 
having difficulty or pain when passing urine (water), recently had a fever, bloody 
stools, or have had abnormal vaginal bleeding or discharge. 
Pregnancy 
Mebeverine is suitable to take during pregnancy. 
 It is sensible to limit use of medication during pregnancy whenever possible. 
However, your doctor may decide that the benefits outweigh the risks in individual 
circumstances and after a careful assessment of your specific health situation. 
Breast feeding 
Mebeverine is suitable to take if you are breastfeeding. 
It is sensible to limit use of medication during breastfeeding whenever possible.  
Marketed Products Available: 
 Mebeverine is presented in the United Kingdom as a (135 mg) tablet. Other 
strengths: 100 mg tablet and 200 mg capsule. 
 It was first registered in 1965. It is manufactured and marketed as Colofac, 
Duspatal and Duspatalin by Solvay Pharmaceuticals. 
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2.3. POLYMERS AND EXCIPIENTS PROFILE:   
                                                                                                           (Rowe R C, 4th edition)             
2.3.1. HYDROXY PROPYL METHYL CELLULOSE 
Synonyms:  Benecel, HPMC, Methocel, Hydroxy propyl methyl cellulose 
Molecular weight: 10,000-15,000 
Structure: 
                       
Description : slightly off-white to beige powder in appearance and may 
be formed into granules. 
Colour  : white to yellowish white 
Odour   : odorless or nearly odorless 
Taste   : bland taste 
Texture  : powder 
Acidity / Alkalinity : pH 5.5-8.0 for a 1%w/w aqueous solution. 
Viscosity for 2 %( w/v) aqueous solution:   4000mpas (Viscosity measured at 200C) 
 Solubility: 
  Soluble in cold water, forming a viscous colloidal solution, practically insoluble 
in mixtures of ethanol and dichloromethane, mixtures of alcohol and water 
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Functional category:   
Coating agent, film former, and rate controlling polymer for sustained release, 
stabilizing agent, suspending agent and viscosity builder. 
Applications in pharmaceutical technology: 
High viscosity grades may be used to retard the release of drugs from a matrix at 
levels of 10-80%w/w in tablets and capsules. 
Stability and Storage:  
Stable between pH 3-11, should be stored in a well-closed container in a cool and 
dry place. 
Incompatibilities:  
Incompatible with some oxidizing agents such as hydrogen peroxide, potassium 
permanganate. 
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                                            2.3.2. EUDRAGIT S100 
Synonyms   : Methacrylic Acid-Methacrylate Copolymer (1:2). 
C.A.S. No.   : 25086 – 15 – 1  
Structure   :                  
                  
Chemical/IUPAC name : Poly (methacylic acid-co-methyl methacrylate) 1:2 
 INCI name   :  Acrylates Copolymer 
Description   : White powders with a faint characteristic odour. 
Solubility:            
1gm of Eudragit S 100 dissolves in 7 g methanol, ethanol,in aqueous isopropyl 
alcohol ethanol, and acetone (containing approx.3% water),as well as in 1N NaOH  to 
give clear to slight cloudy solution. 
Film formation:  
When the test solution is poured onto a glass plate, a clear film forms upon 
evaporation of the solvent. 
Characteristics: 
 Granulation of drug substances in powder form for controlled release 
 Effective and stable enteric coatings with a fast dissolution in the upper Bowel 
 Site specific drug delivery in intestine by combination with Eudragit S grades 
 Variable release profiles 
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Applications:  
 Eudragit is widely used in oral pharmaceutical formulations, especially in 
targeting drug delivery system in GIT. Eudragit is used to prepare sustained-release 
preparations. 
Loss on Drying:  Max. 5.0 % according to "Dry substance / Residue on evaporation." 
Viscosity (dynamic): 50 - 200 mPas.                                                          
Stability and Storage:  
Minimum stability dates are given on the product labels and batch-related 
Certificates of Analysis. Protect from warm temperatures (USP, General Notices). Protect 
against moisture 
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2.3.2. EUDRAGIT L100 
Synonyms   : Methacrylic Acid-Methacrylate Copolymer (1:1). 
C.A.S. No.   :  25086 – 15 – 1 
 Structure   :                          
                                             
Chemical/IUPAC name : Poly (methacylic acid-co-methyl methacrylate) 1:1 
 INCI name   : Acrylates Copolymer 
Description   : White powders with a faint characteristic odour. 
Solubility:             
1gm of Eudragit L 100 dissolves in 7 g methanol, ethanol,in aqueous isopropyl 
alcohol and acetone (containing approx.3% water),as well as in 1N NAOH  to give clear 
to slight cloudy solution. 
Film formation:  
When the test solution is poured onto a glass plate, a clear film forms upon 
evaporation of the Solvent. 
Characteristics: 
 Granulation of drug substances in powder form for controlled release 
 Effective and stable enteric coatings with a fast dissolution in the upper Bowel 
 Site specific drug delivery in intestine by combination with Eudragit S grades 
 Variable release profiles 
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Applications:  
 Eudragit is widely used in oral pharmaceutical formulations, especially in 
targeting drug delivery system in GIT. Eudragit is used to prepare sustained-release 
preparations. 
Loss on Drying: Max. 5.0 % according to "Dry substance / Residue on evaporation." 
Viscosity (dynamic): 50 - 200 mPas.                                                          
Stability and Storage:  
Minimum stability dates are given on the product labels and batch-related 
Certificates of Analysis. Protect from warm temperatures (USP, General Notices). Protect 
against moisture 
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3. AIM AND OBJECTIVES 
 
 Mebeverine Hydrocloride is used an anti-spasmodic agent mainly used in 
treatment of IBD’s(Irritable bowl disease).Mebeverine is the most active and 
exceptionally safe anti-inflammatory action as compared to any other NSAID in its class. 
Therefore Mebeverine hydrocloride was selected to carry out present work which is 
aimed to develop colon targeted micro pellets prepared by for treatment of IBD’s. In 
order to treat the colonic diseases more effectively than conventional delivery systems, 
such a drug delivery system is required which will be able to target the drug to diseased 
colon. The colon specific drug delivery has achieved the most important because the 
colon is an area that is vulnerable to a no.of disease including ulcerative disease, crohn’s 
disease, IBD’s and carcinomas. Treatment of this disease with colonic specific drug 
delivery system provides an interesting alternative over systemic drug administration 
because of lower dosing and fewer systemic side effects. Colon targeted drug delivery 
system (colon targeted micro pellets) inhibits drug release in stomach and small intestine 
and releases most of the drug into colonic region. Thus availability of drug at targeted site 
will be near to 100%.  
To improve the site specificity of pH dependent systems (because of large 
variation in pH of GIT) and variable results with time dependent systems (variation in the 
gastric emptying time and small intestine transit time) led to development of alternative 
approaches for colon specific drug delivery based on various carriers (that are being 
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degraded by colonic bacterial action) like pectin and its salts, chondrotin sulphate, 
amylose, inulin HP, and guar gum etc. 
The present project is based on to develop a novel micro pellets prepared by 
powder layering technique being the most widely used today. The study was under taken 
with aim to develop colon targeted micro pellets dosage form for mebeverine 
hydrochloride.  
 Objectives: 
The objective of the present study is preparing the micropellets of mebeverine 
hydrochloride in order to provide controlled release and colon targeting. The micro 
pellets of mebeverine hydrochloride were formulated by powder layering technique and 
further coating with eudragit L100 and eudragit S100.The micro pellets is evaluated with 
respect to particle size, drug content, entrapment efficiency and loose surface crystal 
study.  Drug polymer compatibility studied by FTIR and DSC. In-vitro drug release 
study, release kinetics studies and stability studies.  
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4. PLAN OF WORK 
 
 Literature survey.  
 Materials and equipments. 
   Preformulation studies. 
 Characterization of Drug. 
 Appearance. 
 Melting Point Determination. 
 Solubility Study. 
 UV Spectroscopy (λmax). 
 IR Spectroscopy. 
 Loss on drying. 
 Drug - Polymers Interaction Studies. 
 Fourier transforms Infra-Red (FTIR) Spectroscopy Study. 
 Differential Scanning Calorimetry (DSC) Analysis. 
 Preparation of Mebeverine hydrochloride micropellets. 
 Evaluation of Mebeverine hydrochloride micropellets. 
 Appearance. 
 Particle size. 
 Micromeritic properties for micropellets. 
 Evaluation of micropellets. 
 Content uniformity. 
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 Loose surface crystal studies. 
 Loss on drying. 
 Scanning electron microscopy. 
 Invitro drug release studies. 
 Release drug data model fitting. 
 Results and Discussion. 
 Summary and Conclusion. 
 Future Prospects. 
 Bibliography. 
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5. MATERIALS AND EQUIPMENTS 
 
5.1. List of Materials used with Sources 
Table 9: List of Materials and their Suppliers 
S. 
No. Name of Material Supplied by 
1 Mebeverine Hydrochloride Bindu pharmaceuticals, Hyderabad. 
2 PVP K30 Richer health care, Hyderabad. 
3 Lactose pellets Bindu pharmaceuticals, Hyderabad. 
4 HPMC K4m Richer health care, Hyderabad. 
5 Eudragit L100 Richer health care, Hyderabad. 
6 Eudragit S100 Richer health care, Hyderabad. 
7 Iso propyl alcohol Richer health care, Hyderabad. 
8 Water Richer health care, Hyderabad. 
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5.2.  List of Equipments used with model: 
         Table 10 : List of equipments with their make  
S. 
No. Name of the equipment Make 
1  Electronic balance Shimadzu, Japan 
2 UV-Visible spectrophotometer Shimadzu, Japan 
3 Standared coating pan Ganson-india 
4 FTIR Spectrophotometer Shimadzu 
5 DSC test apparatus                   Mettler Teldo 
6 Dissolution test apparatus  Vigo Scientifics,  Mumbai 
7 Digital pH meter  Elico Scientifics,  Mumbai 
8 Hot air oven Precision scientific co., Chennai 
9 Humidity chamber Lab tech, Ambala 
10 Tap density apparatus Indo labs, Chennai 
11 Melting point test apparatus Precision scientific co., Chennai 
12 Optical microscope Mettler Toledo 
13 SEM Merlin-FE-SEM 
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6. PRE-FORMULATION STUDIES 
 
6.1. Characterization of Drug:  
6.1.1. Colour and Appearance:                                      (Indian Pharmacopoeia, 2007) 
 The sample was observed visually. 
6.1.2. Melting Point:                                                        (Indian Pharmacopoeia, 2007)             
Melting point of drug was determined by Melting point test apparatus. 
6.1.3. Solubility:                                                                (Indian Pharmacopoeia, 2007) 
Solubility study was carried out as per the I.P.2007.In this maximum amount of 
solvent required to dissolve the solute was determined.  
6.1.4. Spectral Analysis of Mebeverine Hydrochloride:  
                                                           (Indian Pharmacopoeia, 2007; Zayed S.I.M, 2005) 
6.1.4.1. UV Spectral Analysis of Mebeverine: 
6.1.4.1.1. UV Spectral Analysis of Mebeverine in methanol: 
6.1.4.1.1.1. Determination of absorption maximum in methanol: 
A stock solution of Mebeverine (100 µg/ml) was prepared by dissolving 10 mg of 
drug in methanol and final volume was made to100 ml. A dilution of (25 µg/ml) was kept 
in cuvette. The solution was scanned in the range of wavelength 200 – 400 nm. The UV 
spectrum showing λmax was recorded using double beam UV-Visible spectrophotometer  
6.1.4.1.1.2. Preparation of Standard Curve of Mebeverine in methanol: 
A stock solution of Mebeverine (100 µg/ml) was prepared by dissolving 10 mg of 
drug in methanol and final volume was made to 100 ml. The solutions in concentration 
range of 5-25 µg/ml were prepared by appropriate dilutions of stock solution. The UV 
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absorbances of these solutions were determined spectrophotometrically at λmax 263 nm 
using double beam UV-Visible spectrophotometer.  
6.1.4.1.2. UV Spectral Analysis of Mebeverine by using 0.1N HCl: 
6.1.4.1.2.1. Determination of absorption maximum in 0.1N HCl: 
A stock solution of Mebeverine (100 µg/ml) was prepared by dissolving 10 mg of 
drug in 0.1N HCl and final volume was made to 100 ml. A dilution of 25 µg/ml was kept 
in cuvette. The solution was scanned in the range of wavelength 200 – 400 nm. The UV 
spectrum showing λmax was recorded using double beam UV-Visible spectrophotometer.  
6.1.4.1.2.2. Preparation of Standard Curve of Mebeverineine in 0.1N HCl: 
A stock solution of Mebeverine (100 µg/ml) was prepared by dissolving 10 mg of 
drug in 0.1N HCl and final volume was made to 100 ml. The solutions in concentration 
range of 5 -25 µg/ml were prepared by appropriate dilutions of stock solution. The UV 
absorbances of these solutions were determined spectrophotometrically at λmax 263.4 
nm using double beam UV-Visible spectrophotometer.  
6.1.4.1.3. UV Spectral Analysis of Mebeverine by using Phosphate buffer pH 6.8: 
6.1.4.1.3.1. Determination of absorption maximum in Phosphate buffer pH 6.8: 
A stock solution of Mebeverine (100 µg/ml) was prepared by dissolving 10 mg of 
drug in Phosphate buffer pH 6.8 and final volume was made to 100 ml. A dilution of     
25 µg/ml was kept in cuvette. The solution was scanned in the range of wavelength 200 - 
400 nm. The UV spectrum showing λmax was recorded using double beam UV-Visible 
spectrophotometer.  
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6.1.4.1.3.2. Preparation of Standard Curve of Mebeverine in Phosphate buffer pH 
6.8: 
A stock solution of Mebeverine (100 µg/ml) was prepared by dissolving 10 mg of 
drug in Phosphate buffer pH 6.8 and final volume was made to 100 ml. The solutions in 
concentration range of 5 - 25 µg/ml were prepared by appropriate dilutions of stock 
solution. The UV absorbances of these solutions were determined spectrophotometrically 
at λmax 263 nm using double beam UV-Visible spectrophotometer.  
6.1.4.1.4. UV Spectral Analysis of Mebeverine by using Phosphate buffer pH 7.4:   
6.1.4.1.4.1. Determination of absorption maximum in Phosphate buffer pH 7.4:  
                 A stock solution of Mebeverine (100 µg/ml) was prepared by dissolving 10 mg 
of drug in Phosphate buffer pH 6.8 and final volume was made to 100 ml. A dilution of 
(25 µg/ml) was kept in cuvette. The solution was scanned in the range of wavelength 200 
– 400 nm. The UV spectrum showing λmax was recorded using double beam UV-Visible 
spectrophotometer.  
6.1.4.1.4.2. Preparation of Standard Curve of Mebeverine in Phosphate buffer 
 pH 7.4: 
A stock solution of Mebeverine (100 µg/ml) was prepared by dissolving 10 mg of 
drug in Phosphate buffer pH 7.4 and final volume was made to 100 ml. The solutions in 
concentration range of (5 -25 µg/ml) were prepared by appropriate dilutions of stock 
solution. The UV absorbances of these solutions were determined spectrophotometrically 
at λmax 263 nm using double beam UV-Visible spectrophotometer. 
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6.1.5. Infrared Spectrum:                                       (Robert M. Silverstein, 2003) 
The infrared spectrum of Mebeverine was recorded by using FTIR (Perkin elmer-
Pharmaspec-1) instrument. A small quantity of sample was mixed with equal quantity of 
potassium bromide and placed in sample cell to record its IR spectra.  
6.1.6. Loss on drying:                                             (Indian Pharmacopoeia, 2007) 
Loss on drying is the loss of weight expressed as percentage w/w resulting from 
volatile matter of any kind that can be driven off under specified condition. The test can 
be carried out on the well mixed sample of the substance. 
 
 
      Initial weight of substance – Final weight of substance 
Loss on drying =     
                                           Initial weight of substance 
 
6.2. Drug - polymers compatability studies: 
Drug polymers studies holds great importance in designing a formulation In drug 
formulation it is essential to evaluate the possible interactions between the active 
principle and the polymers, as the choice of the polymers should be performed in relation 
to the drug delivery, to their compatibility with the same drug and to the stability of the 
final product. 
 
 
 
 
×100 
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6.2.1. Fourier Transform Infra-Red Spectroscopy (FTIR) Study: 
                                                                        (Robert M. Silverstein, 2003; Becket A. H., 2005) 
Mebeverine powder was mixed with various polymers in the ratio of 1:1. Then, 
the samples were scanned with FTIR (Perkin Elmer-Pharmaspec-1) over a wave number 
range of 4000-400 cm-1. 
6.2.2. Differential Scanning Calorimetry Study (DSC):                 (Jain N. K., 2008) 
Mebeverine powder was mixed with various polymers in the ratio of 1:1.The 
mixture of drug with polymers to maximize the like hood of obscuring an interaction. 
Mixture should be examined under Nitrogen to eliminate oxidative and pyrolytic effect at 
a standard heating rate (100C/minute) on DSC. Over a temperature range, which will 
encompass any thermal changes due to the mixture of drug with polymers? Thermo 
grams of pure drug are used as a reference.      
Appearance or disappearance of one or more peaks in thermo grams of drug with 
polymer are considered as an indication of interaction. 
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7. FORMULATION OF MICROPELLETS 
 
Table 11: Composition of Colon Targeted Micropellets of Mebeverine 
hydrochloride: 
S. 
No. 
Ingredients 
(mg/capsule) 
Formulations Code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Mebeverine HCl 20 20 20 20 20 20 20 20 20 
2 PVP K30 6 6 6 6 6 6 6 6 6 
3 Lactose pellets 160 150 140 160 150 140 140 150 160 
4 HPMC K4M 6 8 10 6 8 10 10 8 6 
5 Eudragit S100 8 16 24 - - - 12 8 4 
6 Eudragit L100 - - - 8 16 24 12 8 4 
7 Isopropyl 
alcohol q.s q.s q.s q.s q.s q.s q.s q.s q.s 
8 Water q.s q.s q.s q.s q.s q.s q.s q.s q.s 
 Total fill weight 200 200 200 200 200 200 200 200 200 
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Coating of pellets: 
There are three stages in coating of micro pellets 
  Drug loading. 
 Drying. 
 Sub coating with polymers. 
 
Preparation of mebeverine HCl micropellets: 
The micropellets of Mebeverine hydrochloride were prepared by pan coating 
powder layering technique. The formulation of delayed release micropellets of 
mebeverine hydrochloride were done by using polymers HPMC K4M, Eudragit L100, 
Eudragit S100. 
 
Drug Loading: 
Lactose pellets were sieved through 30#40 sieves and pellets was taken for drug 
loading from total batch size, required quantity of drug was taken and dispersed in binder 
solution stirred for 10min and pellets were loaded with drug by coating of drug with 
binder solution. The drug loaded micropellets were dried at 450 C for 8 hours in stainless 
steel tray drier. Check moisture content, it should be below 1%. Then pass the pellets 
through sifters to remove fines. 
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Coating with polymers: 
Drug loaded micropellets were coated with coating polymers(HPMC K4M, 
Eudragit L100, Eudragit S100)in different ratios. Spay the coating solution through 
nozzle on pellets along with continuous flow of warm air in, to dry the coat as soon as it 
forms uniform coating. 
 
 
  
 
 
 
 
 
 
 
 
         
 
 
  
        EVALUATION        
OF MICROPELLETS.... 
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8. EVALUATION OF MICROPELLETS 
 
 Evaluation of Micropellets: 
 Micromeritic Properties of Micropellets. 
 Appearance. 
 Particle size. 
 Angle of repose. 
 Bulk density. 
 Tapped density. 
 Carr’s index. 
 Hausner’s ratio. 
 Evaluation of Micropellets. 
 Drug content. 
 Loose surface crystal study. 
 Loss on drying. 
 Scanning electron microscopy. 
 In-vitro drug release studies. 
 Release drug data model fitting. 
 Stability Studies. 
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8.1. MICROMERITIC PROPERTIES OF MICROPELLETS: 
8.1.1. Appearance:                                                    
 The pellets were visually observed for physical appearance of pellets. 
 
8.1.2. Particle size:                                                  (Choudhury P.K  et al,2010) 
 Particle size distribution of micropellets was determined by optical microscopy 
using calibrated ocular eye piece. Fifty micropellets were evaluated and the experiment 
was performed. Geometric mean diameter was then calculated using the equation. 
Xg=10 X [(niXlogXi)/N] 
Xg is geometric mean diameter, ni is number of particles in the range, Xi is the midpoint 
of range, N is total number of particles analyzed. 
 
8.1.3. Angle of repose: 
 The dried micropellets were allowed to fall freely through a funnel fixed at 1 cm 
on a horizontal surface and the angle of repose (θ) was measured. 
θ = tan-1h/r. 
Where h is the height of the heap, r is the radius. 
 
8.1.4. Bulk density and tapped density: 
An accurately weighed (10 gm) pellets from each formula was lightly shaken to 
break any agglomerates formed and it was introduced into a measuring cylinder. The 
volume occupied by the pellets was measured which give bulk volume. The measuring 
cylinder was tapped until no further change in volume was noted which gave the tapped 
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volume. Both Bulk Density (BD) and Tapped Bulk Density (TBD) of pellets were 
determined using the following formulae. 
BD = Weight of the pellets/Volume of the pellets 
TBD = Weight of the pellets/Tapped volume of the pellets 
8.1.5. Carr’s Compressibility Index: 
The compressibility index of the pellets was determined using following Carr’s 
compressibility index formula. 
                  Carr’s Compressibility Index (%) = [(TBD-LBD)/ TBD] x100 
Relationship   between % compressibility and flow ability is shown in the Table 12. 
Table 12:  Relationship between % Compressibility and Flow ability 
S. No. % Compressibility Flow ability 
1 5-15 Excellent 
2 12-16 Good 
3 18-21 Fair Passable 
4 23-35 Poor 
5 33-38 Very poor 
6 >40 Very very poor 
 
8.1.6. Hausner’s ratio: 
Hausner’s ratio is the ratio between tapped density and bulk density. Hausner’s 
ratio less than 1.25 indicates good flow properties while Hausner’s ratio greater than 1.25 
shows poor flow of granules. 
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Table 13:  Relationship between Hausner’s ratio and Flow ability 
S. No. Hausner’s ratio Flow Property 
1 0.0 - 1.25 Free flow 
2 1.25 - 1.6 Cohesive flow 
 
8.2.EVALUATION OF MICROPELLETS:     (choudhury P.K et al, 2010) 
8.2.1. Drug Content:  
200mg pellets were weighed and powdered, a quantity of powder equivalent to 20 
mg of each formulation was transferred to a 25 ml volumetric flask and 15 ml water is 
added.  The drug is extracted in water by vigorously shaking the stoppered flask for 15 
minutes.  Then the volume is adjusted to the mark with distilled water and the liquid is 
filtered.  The drug content was determined by measuring the absorbance at 263 nm after 
appropriate dilution. The drug content was calculated using the standard calibration 
curve.  The mean percent drug content was calculated.  
8.2.2. Loose surface crystal study:            ( choudhury P.K  et al, 2010) 
About 200 mg of micropellets were accurately weighed and suspended in 
phosphate buffer pH6.8. They were shaken vigorously for 5 min. The leaked out solution 
is analyzed spectrophotometrically at 263 nm. 
8.2.3. Loss on drying:  
Loss on drying is the loss of weight expressed as percentage w/w resulting from 
volatile matter of any kind that can be driven off under specified condition. The test can 
be carried out on the well mixed sample of the substance. 
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      Initial weight of substance – Final weight of substance 
Loss on drying =     
                                           Initial weight of substance 
 
8.2.4. Scanning electron microscopy: 
Morphological examination of the surface and internal structure of the dried beads 
was performed by using a scanning electron microscope (SEM). Micropellets before 
dissolution only subjected to SEM study since, after dissolution the pellets become 
swollen palpable mass. Photographs were taken within the range of 50-500 
magnification. 
8.3. INVITRO DRUG RELEASE STUDIES: 
8.3.1. Drug release studies in 0.1 N HCl:    (Khan M.S et al, 2010; Gang cheng et al.) 
Drug release studies were carried out by using USP dissolution type II test 
apparatus. The pellets were tested for drug release for 2 hours in 0.1N HCl (900ml) as the 
average gastric emptying time is about 2 hours. 5ml of samples were withdrawn at the 
interval of 1 hour and diluted up to 10 ml with 0.1N HCl. The absorbances were 
measured at 263 nm. Using a double beam UV spectrophotometer to find out the amount 
of Mebeverine released from Micropellets. 
 
8.3.2. Drug release studies in pH 6.8 phosphate buffer:             
                                                (Khan M.S et al, 2010; Tereza Bautzová et al, 2011) 
After drug release studies carried out in 0.1 N HCl, the dissolution medium was 
replaced by pH 6.8 phosphate buffer (900ml) and tested for drug release for 3 hours as 
×100 
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the average small intestinal transit time is about 3 hours. 5ml of samples were withdrawn 
at the interval of 1 hour and diluted up to 10 ml with pH 6.8 phosphate buffer. The 
absorbance was measured at 263 nm, using a double beam UV spectrophotometer to find 
out the amount of Mebeverine released from Micropellets. 
8.3.3. Drug release studies in pH 7.4 phosphate buffer:                    
After drug release studies carried out in pH 6.8 phosphate buffer, the dissolution 
medium was replaced by pH 7.4 phosphate buffer (900ml) and tested for drug release for 
3 hours as the average small intestinal transit time is about 5-12 hours. 5ml of samples 
were withdrawn at the interval of 1 hour and diluted up to 10 ml with pH 7.4 phosphate 
buffer. The absorbance was measured at 263 nm, using a double beam UV 
spectrophotometer to find out the amount of Mebeverine released from Micropellets. 
                        Table14. Parameters for In Vitro Drug Release 
1 Apparatus USP type II apparatus (Paddle type) 
2 Temperature 37 +  0.5° C 
3 Initial Volume 900ml 
4 Speed 100 rpm 
5 Drawn volume 5 ml 
6 Running time 2 hrs in 0.1N HCl, 3 hrs in phosphate buffer 
pH 6.8 and 7 hrs in phosphate buffer pH 7.4. 
7 Medium Replacement Media refilling at 2 hrs and 5hrs 
 
 
 
 
 
 
Colon Targeted Micropellets of Mebeverine HCl                    Evaluation of Micropellets 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 89 
 
8.4. RELEASE DRUG DATA MODEL FITTING:  (Choudhury P.K  et al, 2010) 
 The suitability of several equation that are reported in the literature to identify 
the mechanisms for the release of drug was tested with respect to the release data up to 
the first 50% drug release. The data were evaluated according to the following equations. 
Zero order model.  
             Mt=M0 + K0 t 
Higuchi model. 
             Mt=M0 + KH t0.5 
Korsmeyer-peppas model. 
             Mt=M0 + Kk tn  
 Where Mt is the amount of the drug dissolved in time t. M0 is the initial amount of 
drug. K0 is the Zero order release constant, KH is the Higuchi rate constant, KK is a 
release constant and n is the release exponent that characterizes the mechanism of drug 
release. 
8.5. STABILITY STUDIES:                              (Janes T., 2000, Singh S.K  et al,2009)
 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling recommended 
storage conditions, re-test periods and shelf-lives. Generally, the observation of the rate at 
which the product degrades under normal room temperature requires a long time. To 
avoid this undesirable delay, the principles of accelerated stability studies are adopted. 
The International Conference on Harmonization (ICH) Guidelines titled “Stability testing 
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of New Drug Substances and Products” describes the stability test requirements for drug 
registration application in the European Union, Japan and the States of America. 
Stability studies were carried out at 40°C / 75% RH for the optimized formulation 
for 3 months. The micropellets were stored at 40°C/75% RH as per ICH guidelines and 
various parameters(drug content and drug release profile) were monitored periodically for 
3 months. 
 
  
 
 
 
 
 
 
 
            
 
 
 
 
              RESULTS & 
       DISCUSSION.... 
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9. RESULTS AND DISCUSSION 
  
9.1. CHARACTERIZATION OF DRUG: 
9.1.1. Colour and Appearance: 
The drug (Mebeverine HCl) colour is “White or off white Powder” as same as the 
reported reference. 
9.1.2. Melting Point: 
The Melting point of Mebeverine HCl was found to be 130.5ºC.  The reported 
melting point of Mebeverine is 129ºC-131ºC. Hence, observed values are complies with 
IP.  
9.1.3. Solubility Study: 
The Solubility of Mebeverine HCl in different solvents is given below: 
Table 15: Solubility of Mebeverine in Different Solvents 
 
S. No. 
 
Solvent 
Parts of solvent 
required per part of 
solute 
 
Inference 
1 Distilled water 0.9 Very soluble. 
2 Ethanol (95%) 7 Freely soluble. 
3 0.1 N HCl 550  Slightly  soluble. 
5 Phosphate buffer pH 7.4 700 Slightly soluble. 
6 Phosphate buffer pH 6.8  900   Slightly soluble. 
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9.1.4. SPECTROSCOPIC STUDIES: 
9.1.4.1. UV Spectroscopy: 
9.1.4.1.1. Determination of λmax and Preparation of Calibration Curve of            
               Mebeverine by using methanol: 
UV absorption spectrum of Mebeverine in methanol shows λmax at 263 nm. 
Absorbance obtained for various concentrations of Mebeverine in water are given in 
Table 16. The graph of absorbance concentration for Mebeverine was found to be linear 
in the concentration range of 5 – 25 µg /ml. The drug obeys Beer- Lambert’s law in the 
range of 5 – 25 µg /ml. 
 
  
  
 
 
Fig. 14: Absorption maximum of Mebeverine in methanol 
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Table 16: Concentration and Absorbance data for Calibration Curve of Mebeverine 
in methanol 
S. No. Concentrations(µg/ml) Absorbance at 263 nm 
1                   Blank 0 
1 5 0.0920 
2 10 0.1840 
3 15 0.2761 
4 20 0.3680 
5 25 0.5150 
          
        
 
Fig. 15: Calibration Curve of Mebeverine in methanol 
The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the Table 17. 
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Table 17:  Data for Calibration Curve parameters of Mebeverine in methanol 
S. No. Parameters Values 
1 Slope 0.0184 
2 Intercept 0.0219 
3 Correlation coefficient (R) 0.9989 
 
9.1.4.1.2. Determination of λmax and Preparation of Calibration Curve of 
Mebeverine by using 0.1N HCl 
UV absorption spectrum of Mebeverine in 0.1N HCl shows λmax at 263.4 nm. 
Absorbance obtained for various concentrations of Mebeverine in 0.1N HCl are given in 
Table 18. The graph of absorbance versus concentration for Mebeverine was found to be 
linear in the concentration range of 5 – 25 µg /ml. The drug obeys Beer- Lambert’s law in 
the range of 5– 25 µg /ml. 
                                                                                                                                                                            
                                                                                        
 
                  
                          Fig. 16: Absorption maximum of Mebeverine in 0.1N HCl 
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Table 18: Concentration and Absorbance data for Calibration Curve of Mebeverine 
in 0.1N HCl 
S. No. Concentrations (µg/ml) Absorbance at 263.4nm 
1 Blank 0 
2 5 0.166 
3 10 0.329 
4 15 0.488 
5 20 0.632 
6 25 0.789 
         
 
Fig. 17: Calibration curve of Mebeverine in 0.1N HCl 
The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the Table 19. 
 Table 19:  Data for Calibration Curve parameters of Mebeverine in 0.1N HCl 
S. No. Parameters Values 
1 Slope 0.0317 
2 Intercept 0.0058 
3 Correlation coefficient (R) 0.9997 
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9.1.4.1.3. Determination of λmax and Preparation of Calibration Curve of 
Mebeverine by using Phosphate buffer pH 6.8: 
UV absorption spectrum of Mebeverine in pH6.8 phosphate buffer shows λmax at 
263 nm. Absorbance obtained for various concentrations of Mebeverine in Phosphate 
buffer pH 6.8 are given in Table 20. The graph of absorbance versus concentration for 
Mebeverine was found to be linear in the concentration range of 5 – 25 µg /ml. The drug 
obeys Beer- Lambert’s law in the range of 5 – 25 µg /ml. 
 
                   
                                   
 
 
     Fig. 18: Absorption maximum of Mebeverine in Phosphate buffer pH 6.8 
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Table 20: Concentration and Absorbance data for Calibration Curve of Mebeverine 
in Phosphate buffer pH 6.8 
S. No. Concentrations (µg/ml) Absorbance at 263 nm 
1 Blank 0 
2 5 0.165 
3 10 0.291 
4 15 0.424 
5 20 0.584 
6 25 0.728 
     
 
      Fig. 19: Calibration Curve of Mebeverine in Phosphate buffer pH 6.8 
The values of Correlation coefficient (R), Slope, Intercept obtained from the calibration       
curve are given in the Table 21. 
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Table 21:  Data for Calibration Curve parameters of Mebeverine in Phosphate 
buffer pH 6.8 
S. No. Parameters Values 
1 Slope 0.0285 
2 Intercept 0.0074 
3 Correlation coefficient (R) 0.9993 
 
9.1.4.1.4. Determination of λmax and Preparation of Calibration Curve of 
Mebeverine by using Phosphate buffer pH 7.4: 
UV absorption spectrum of Mebeverine in pH7.4 phosphate buffer shows λmax at 
263 nm. Absorbance obtained for various concentrations of Mebeverine was found to be 
linear in the concentration range of 5 – 25 µg /ml. The Mebeverine absorbance in 
Phosphate buffer pH 7.4 is given in Table 22. The graph of absorbance concentration for 
drug obeys Beer- Lambert’s law in the range of 5 – 25 µg /ml. 
 
                           
  
 
Fig. 20: Absorption maximum of Mebeverine in Phosphate buffer pH 7.4          
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Table 22: Concentration and Absorbance data for Calibration Curve of Mebeverine 
in Phosphate buffer pH 7.4 
S. No. Concentration (µg/ml) Absorbance at 263 nm 
1 blank 0 
2 5 0.144 
3 10 0.333 
4 15 0.524 
5 20 0.734 
6 25 0.945 
      
 
Fig. 21: Calibration curve of Mebeverine in Phosphate buffer pH 7.4  
The values of Correlation coefficient (R), Slope, Intercept obtained from the calibration 
curve are given in the following table23. 
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Table 23:  Data for Calibration Curve parameters of Mebeverine in Phosphate 
buffer pH 7.4  
S. No. Parameters Values 
1 Slope 0.037 
2 Intercept -0.0226 
3 Correlation coefficient (R) 0.9996 
 
 
9.1.4.2. Fourier Transform Infra-Red Spectroscopy (FTIR): 
The IR spectrum of Mebeverine is shown in figure 22. The Interpretation of IR 
frequencies are shown in Table 24. 
 
Fig. 22:  IR Spectrum of Mebeverine HCl 
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Interpretation of IR Spectrum: 
Table 24 shows the peaks observed at different wave numbers and the functional 
group associated with these peaks. The major peaks are identical to functional group of 
Mebeverine. Hence, the sample was confirmed as Mebeverine HCl.  
Table 24: Characteristic Frequencies in IR Spectrum of Mebeverine 
Functional groups Wave No. (cm-1) 
C-H Stretching 2995.58 
C=O Stretching 1717.68 
C=C Ring stretch 1559.51-1509.36 
C-N Stretching 1399.62 
 
 
9.1.5. Loss on drying: 
The percentage loss on drying after 5 hours was found to be 0.208±0.003%. The 
sample passes test for loss on drying as per the limits specified in IP.  
Table 25: Loss on drying of Mebeverine 
S. No. Percentage Loss on drying 
(%) 
Average LOD 
(%) 
1 0.205  
0.208±0.003 2 0.206 
3 0.214 
All the values are expressed as a mean ± SD., n = 3 
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9.2.  DRUG - POLYMERS COMPATIBILITY STUDIES: 
9.2.1. Fourier Transform Infra-Red Spectroscopy (FTIR): 
 
 
  
 
 
 
 
 
 
 
 
             
 
 
A. 
B. 
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Fig. 23: IR Spectra of  
 A. Mebeverine HCl. 
 B. Mebeverine HCl + HPMC K4M 
 
 
C. 
D. 
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 C. Mebeverine HCl + Eudragit L100 
 D. Mebeverine HCl + Eudragit S100 
From the above figures, it can be seen that, the major functional group peaks 
observed in spectra’s of Mebeverine with HPMC K4M, Mebeverine with Eudragit L100 
and Mebeverine with Eudragit S100 remains unchanged as compared with spectra of 
Mebeverine HCl. So from the above IR spectra it can be observed that there is no 
interaction between Mebeverine HCl and Polymers used in the formulations. 
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9.2.2. Differential Scanning Calorimetry (DSC): 
         
          B.       
 
               
          
A. 
C.    
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Fig.24. Thermo gram of   A. Mebeverine HCl 
             B. Mebeverine HCl + Eudragit L100 
                                  C. Mebeverine HCl + HPMC 
                    D. Mebeverine HCl+ Eudragit S100 
             
The results of DSC studies are given in above figures. Pure Mebeverine HCl 
showed sharp endotherm at 130°C corresponding to its melting point. There was no 
appreciable change in the melting endotherms of Mebeverine with HPMC K4M, 
Mebeverine with Eudragit L100 and Mebeverine with Eudragit S100 as compared to the 
thermo gram of Mebeverine HCl. So, it could be concluded that there is no interaction 
between Mebeverine HCl and Polymers used in the formulations.  
 
 
 
 
D. 
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9.3. MICROMERITIC PROPERTIES OF MEBEVERINE HCl MICROPELLETS: 
9.3.1. Appearance: 
Table 26: General appearance study of micropellets 
Parameters Fc F1-F3 F4-F6 F6-F9 
Composition ---- Eudragit L100 Eudragit 
S100 
Both Eudragit 
L100 and Eudragit 
S100 
Shape Spherical Spherical Spherical Spherical 
Size by 
visualization 
Small Large than 
control 
Large in 
size 
Large in size 
Colour Creamish 
white 
More white 
than control 
White 
pellets 
White pellets 
Stickiness None None None None 
Odour No No No No 
 
9.3.1.1.  Appearance: 
 The scanning electron microscope shows the pellets being spheroid  in shape and 
showing smooth surface of pellets. 
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9.3.2.   Particle size: 
Table 27: particle size for various formulations of micropellets 
Formulations 
Code 
Particle size 
(µm ± S.D) 
F1 500±0.50 
F2 640±0.32 
F3 690±0.41 
F4 610±0.45 
F5 670±0.43 
F6 658±0.32 
F7 759±0.34 
F8 789±0.54 
F9 775±0.36 
                            All the values are expressed as a mean ± SD., n = 3 
9.3.2.1.  Particle size: 
  The size of micro pellets found to be in the range of 500 µm to 790 µm and it 
was observed that increase in concentration of coating polymer particle size of the micro 
pellets significantly increased. The average particle size is highest for F8. The particle 
size distribution is uniform and narrow. 
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Table 28: Micromeritic Properties of Prepared micropellets 
Formulations 
Code 
Angle of 
Repose  
(o) 
BD 
(gm/ml) 
TBD 
(gm/ml) 
Carr’s 
Index (%) 
Hausner’s 
ratio 
F1 24.23±0.02 0.923±0.01  0.989±0.01  5.47 1.07 
F2 24.23±0.02       0.931±0.01 0.984±0.01 5.71 1.05 
F3 24.48±0.04 0.921±0.03 0.988±0.04  4.38 1.07 
F4 25.06±1.06 0.934±0.01  0.991±0.02  4.96 1.06 
F5 23.93±0.19  0.915±0.01  0.959±0.03 5.21  1.04 
F6 25.18±0.33  0.952± 0.03 0.999±0.06  5.47 1.04 
F7 25.92±0.15  0.947±0.01  1.028±0.01 5.39 1.08 
F8 24.72±0.15  0.928±0.04  0.972±0.03  5.11 1.04 
F9 23.31±0.04 0.938±0.06  0.987±0.05  4.96 1.05 
All the values are expressed as a mean ± SD., n = 3 
9.3.3. Angle of repose: 
 The results for angle of repose are recorded in Table 28. Angle of repose ranged 
from 23.31 ± 0.04 to 25.92 ± 0.15. The flow properties of micropellets in all formulations 
exhibit good flow. 
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9.3.4. Bulk density and Tapped bulk density:  
 The results are shown in Table 28. The values of BD and TBD were found to be 
in the range from 0.915±0.01 to 0.952±0.03 gm/ml and from 0.999±0.06 to 1.028±0.01 
gm/ml respectively. So, it shows that all formulations having good flow properties and 
pack ability.  
9.3.5. Carr’s Compressibility Index:  
 The results for Carr’s Compressibility Index are recorded in Table 28. The Carr’s 
Compressibility Index were in the ranged from 4.38 to 5.71 %. This indicates good flow 
properties of micropellets. 
9.3.6. Hausner’s ratio:   
The result were summarized in Table 28. The Hausner’s ratio were found in the 
ranged from 1.04 to 1.08. So it indicates good flow properties. 
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9.4. EVALUATION OF MEBEVERINE HCl MICROPELLETS:  
Table 29: Physico-Chemical Properties of micropellets: 
Formulations 
Code 
Drug 
Content* 
(%) 
Loose surface 
crystal (%) 
Loss on drying 
            (%) 
F1 99.05±0.02 3.201 0.9 
F2 99.30±0.02 2.360 0.8 
F3 98.6±0.015 1.990 0.8 
F4  98.85±0.030 3.891 0.9 
F5        99.2±0.028 3.237 0.7 
F6 98.65±0.025 2.569 0.7 
F7 99.05±0.036 1.786 0.9 
F8 99.65±0.040 1.463 0.8 
F9 99.75±0.026 1.589 0.8 
All the values are expressed as a mean ± SD., n = 3 
  
9.4.1. Drug Content:  
Drug content was found to be uniform among different batches of micropellets 
and ranged from 98.6 to 99.75 %. These results showed that the all formulations having 
percentage drug content within the specified limits as per IP. 
9.4.2. Loose surface crystal study: 
Loose surface crystal study was an important parameter giving an indication of 
the amount of the drug on the surface of the micropellets without proper entrapment.  It 
also conforms net drug loss during process is minimal.  With the increase in the 
copolymer concentration % LSC decreased significantly owing to high entrapment of 
drug in the dense network of polymer. 
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9.4.3. Loss on drying: 
The value of loss on drying was found from 0.7-0.9% and obese the 
pharmacopeia limits (Less than 1%). 
9.4.4. Scanning electron microscope (SEM): 
 
          Fig.25: Scanning electron microscopy of mebeverine HCl loaded micropellets 
with Eudragit L100 
 
 
        Fig.26: Scanning electrone microscopy of mebeverine HCl loaded micropellets 
with Eudragit S100 
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        Fig.27: Scanning electrone microscopy of mebeverine HCl loaded micropellets 
with Eudragit S100 and Eudragit S100. 
The scanning electron microscope shows the pellets being spheroid in shape. 
Surface depression was noted at the point of contact on the drying paper. On comparison 
of the pellets prepared from polymer s in high concentrations more roughness was 
observed with Eudragit polymers. Eudragit S100 produces more smooth surface area as 
compared to others. 
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9.5. IN-VITRO DRUG RELEASE STUDIES: 
9.5.1. IN-VITRO DRUG RELEASE PROFILE OF MICROPELLETS: 
 Drug release Profile for Formulation F1: 
Table 30: In-vitro drug release data of Formulation F1 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
DE 
  (%) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 6.19±0.015 0.72 1.81 0.50 6.19 3 2 6.92±0.010 0.80 2.80 0.59 6.99 
4 pH 6.8 
phosphate 
buffer 
3 10.95±0.010 1.20 3.54 1.24 11.02 
5 4 17.44±0.025 1.85 4.56 2.03 17.51 
6 5 21.04±0.030 2.22 5.69 2.44 21.11 
7 
pH 7.4 
phosphate 
buffer  
6 51.32±0.030 5.24 7.85 4.20 51.39 
8 7 71.5±0.041 7.27 11.19 4.84 71.57 
9 8 74.53±0.020 7.61 14.44 4.96 74.60 
10 10 75.69±0.011 7.77 19.24 5.04 75.76 
11 12 76.98±0.020 7.94 22.58 5.17 77.05 
     All the values are expressed as a mean ± SD., n = 3 
 
                         Fig.28. Cumulative percentage Drug release profile of F1. 
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 Drug release Profile for Formulation F2: 
Table 31: In-vitro drug release data of Formulation F2       
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
DE 
  (%) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 5.61±0.057 0.69 1.73 0.50 5.61 3 2 6.48±0.020 0.75 2.68 0.58 12.09 
4 pH 6.8 
phosphate 
buffer 
3 10.09±0.025 1.13 3.36 1.22 15.70 
5 4 17.01±0.015 1.81 4.35 2.07 22.62 
6 5 20.47±0.020 2.16 5.47 2.47 26.08 
7 
pH 7.4 
phosphate 
buffer  
6 50.60±0.020 5.16 7.61 4.23 56.21 
8 7 71.65±0.020 7.28 10.97 4.89 77.26 
9 8 75.25±0.030 7.68 14.27 5.03 80.86 
10 10 76.55±0.025 7.85 19.18 5.11 82.16 
11 12 77.85±0.026 8.02 22.60 5.24 83.46 
All the values are expressed as a mean ± SD., n = 3 
 
 
                      Fig.29. Cumulative percentage Drug release profile of F2 
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 Drug release Profile for Formulation F3: 
Table 32: In-vitro drug release data of Formulation F3 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
DE 
  (%) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 5.19±0.01 0.62 1.56 0.50 5.91 3 2 6.05±0.020 0.71 2.44 0.63 11.24 
4 pH 6.8 
phosphate 
buffer 
3 9.51±0.015 1.06 3.10 1.24 14.70 
5 4 16.00±0.025 1.71 4.06 2.10 21.19 
6 5 19.75±0.020 2.09 5.14 2.54 24.94 
7 
pH 7.4 
phosphate 
buffer  
6 46.42±0.025 4.75 7.14 4.20 51.61 
8 7 69.05±0.025 7.02 10.32 4.94 74.24 
9 8 73.09±0.036 7.46 13.55 5.09 78.28 
10 10 74.10±0.020 7.60 18.37 5.17 79.29 
11 12 75.11±0.030 7.74 21.70 5.27 80.30 
      All the values are expressed as a mean ± SD., n = 3 
 
 
                 Fig.30. Cumulative percentage Drug release profile of F3 
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 Drug release Profile for Formulation F4: 
Table 33: In-vitro drug release data of Formulation F4 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
DE 
  (%) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 6.77±0.036 0.82 2.06 0.50 6.77 3 2 8.07±0.011 0.97 3.26 0.65 14.84 
4 pH 6.8 
phosphate 
buffer 
3 11.67±0.015 1.36 4.12 1.19 18.44 
5 4 18.45±0.02 2.11 5.26 2.00 25.22 
6 5 22.34±0.030 2.54 6.53 2.43 29.11 
7 
pH 7.4 
phosphate 
buffer  
6 54.35±0.026 6.02 9.01 4.21 61.12 
8 7 74.10±0.045 8.20 12.80 4.81 80.87 
9 8 77.27±0.040 8.59 16.45 4.94 84.04 
10 10 79.43±0.020 8.87 21.89 5.06 86.20 
11 12 81.60±0.026 9.15 25.75 5.25 88.37 
     All the values are expressed as a mean ± SD., n = 3 
 
 
                 Fig.31. Cumulative percentage Drug release profile of F4 
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 Drug release Profile for Formulation F5: 
Table 34: In-vitro drug release data of Formulation F5 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
DE 
  (%) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 6.34±0.026 0.78 1.94 0.50 6.34 3 2 7.06±0.032 0.86 3.01 0.60 13.40 
4 pH 6.8 
phosphate 
buffer 
3 10.95±0.015 1.28 3.79 1.23 17.29 
5 4 17.58±0.020 2.01 4.90 2.05 23.92 
6 5 21.48±0.010 2.44 6.15 2.48 27.82 
7 
pH 7.4 
phosphate 
buffer  
6 52.04±0.015 5.77 8.55 4.22 58.38 
8 7 72.23±0.025 7.99 12.24 4.86 78.57 
9 8 76.55±0.030 8.51 15.87 5.01 82.89 
10 10 79.00±0.020 8.82 21.36 5.16 85.34 
11 12 81.31±0.015 9.12 25.27 5.35 87.65 
All the values are expressed as a mean ± SD., n = 3 
    
 
                          Fig.32. Cumulative percentage Drug release profile of F5 
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 Drug release Profile for Formulation F6: 
Table 35: In-vitro drug release data of Formulation F6 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
DE 
  (%) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 5.91±0.030 0.73 1.82 0.50 5.91 3 2 6.63±0.045 0.81 2.83 0.60 12.45 
4 pH 6.8 
phosphate 
buffer 
3 10.09±0.015 1.19 3.56 1.21 15.91 
5 4 16.72±0.020 1.92 4.61 2.08 22.54 
6 5 21.04±0.02 2.40 5.84 2.56 26.86 
7 
pH 7.4 
phosphate 
buffer  
6 49.88±0.028 5.54 8.17 4.23 55.70 
8 7 70.35±0.030 7.79 11.76 4.88 76.17 
9 8 72.66±0.025 8.08 15.25 4.98 78.48 
10 10 76.41±0.032 8.53 20.51 5.19 82.23 
11 12 79.29±0.020 8.89 24.35 5.43 85.11 
  All the values are expressed as a mean ± SD., n = 3 
 
 
              Fig.33. Cumulative percentage Drug release profile of F6 
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 Drug release Profile for Formulation F7: 
Table 36: In-vitro drug release data of FormulationF7 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
DE 
  (%) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 5.62±0.025 0.84 2.10 0.50 5.62 3 2 6.34±0.015 0.90 3.23 0.57 11.96 
4 pH 6.8 
phosphate 
buffer 
3 9.80±0.010 1.19 3.90 1.03 15.42 
5 4 16.14±0.020 1.71 4.74 1.79 21.76 
6 5 20.04±0.015 2.04 5.67 2.22 25.66 
7 
pH 7.4 
phosphate 
buffer  
6 54.20±0.025 4.83 7.59 4.12 59.82 
8 7 73.38±0.025 6.42 10.52 4.71 79.00 
9 8 77.99±0.021 6.83 13.35 4.87 83.61 
10 10 82.03±0.020 7.20 17.69 5.08 87.65 
11 12 83.75±0.015 7.29 20.78 5.16 89.37 
All the values are expressed as a mean ± SD., n = 3    
 
 
                         Fig.34. Cumulative percentage Drug release profile of F7       
                      
Colon Targeted Micropellets of Mebeverine HCl                           Results and Discussion 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 121 
 
 Drug release Profile for Formulation F8: 
Table 37: In-vitro drug release data of Formulation F8 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
DE 
  (%) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 5.76±0.020 0.85 2.13 0.50 5.76 3 2 6.77±0.02 0.94 3.30 0.59 12.53 
4 pH 6.8 
phosphate 
buffer 
3 12.11±0.015 1.38 4.13 1.20 17.87 
5 4 19.60±0.025 2.00 5.21 1.91 25.36 
6 5 24.22±0.011 2.38 6.36 2.33 29.98 
7 
pH 7.4 
phosphate 
buffer  
6 56.08±0.03 4.99 8.37 3.99 61.83 
8 7 74.68±0.025 6.53 11.29 4.58 80.438 
9 8 76.84±0.020 6.74 14.03 4.67 82.59 
10 10 80.44±0.015 7.07 18.13 4.87 86.99 
11 12 80.88±0.02 7.15 21.03 4.94 87.43 
  All the values are expressed as a mean ± SD., n = 3 
 
 
            Fig.35. Cumulative percentage Drug release profile of F8 
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 Drug release Profile for Formulation F9: 
Table 38: In-vitro drug release data of Formulation F9 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
DE 
  (%) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 6.05±0.030 0.88 2.19 0.50 6.05 3 2 7.06±0.01 0.96 3.39 0.59 13.11 
4 pH 6.8 
phosphate 
buffer 
3 11.67±0.025 1.34 4.18 1.13 17.74 
5 4 19.17±0.025 1.96 5.20 1.88 25.24 
6 5 23.78±0.036 2.35 6.32 2.31 29.85 
7 
pH 7.4 
phosphate 
buffer  
6 55.50±0.030 4.94 8.30 3.98 61.57 
8 7 74.24±0.020 6.50 11.20 4.59 80.31 
9 8 77.56±0.015 6.80 13.96 4.72 83.63 
10 10 80.88±0.025 7.11 18.12 4.90 86.95 
11 12 82.18±0.020 7.25 21.08 5.02 88.25 
All the values are expressed as a mean ± SD., n = 3 
 
 
Fig.36. Cumulative % Drug release profile of formulation F9 
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           Fig.37. Cumulative % Drug release profile of formulation F1 – F9 
The purpose of colon targeted drug delivery system is not only to protect the drug 
from being released in the physiological environment of the Stomach and Intestine but 
also to release the drug in the colon from the micropellets formulation. Hence the ability 
of the polymers used in the formulations (F1 to F9) to retain the integrity of pellets in 
upper GIT were assessed by conducting drug release studies in 0.1N HCl for 2 hours and 
pH 6.8 phosphate buffer for 3 hours (condition mimicking mouth to the colon transit). 
After 5 hours of testing not more than 30% of Mebeverine HCl was released from any 
formulations (F1 to F9). This shows that HPMC K4M, Eudragit L100, Eudragit S100 are 
capable of protecting the drug from being released completely in the physiological 
environment of Stomach and Small Intestine. 
After completing the dissolution study in 0.1 N HCl (900ml) for first two hours 
and in phosphate buffer pH 6.8 (900ml) for next three hours, the dissolution study was 
continued in the phosphate buffer pH 7.4 up to the twelve hours. 
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The drug release from formulation F1, F2 and F3 containing Eudragit L100 (2%, 
4% and 8%) alone was found to be 76.98%, 77.85% and 75.11% after the end of 12 hrs. 
This is due to lesser soluble of drug in the medium. 
The drug released from formulation F4, F5 and F6 containing Eudragit S100 (2%, 
4% and 8%) were 81.60%, 81.31% and 79.29% respectively at the end of 12 hrs. 
The drug released from formulation F7, F8 and F9 containing Eudragit L100 and 
EudragitS100 were 83.75%, 80.88% and 82.18% respectively at the end of 12 hrs. 
The drug released from formulation F7containing Eudragit L100 and Eudragit 
S100 was found to be 83.75% at the end of 12 hrs, which is showing high percentage 
drug release. It protects the drug at stomach pH and small intestine pH environment. 
9.7. RELEASE DRUG DATA MODELING: 
9.7.1. Kinetics of in-vitro drug release:  
 The drug diffusion through most type of polymeric system is often best described 
by Fickian diffusion (diffusion exponent, n=0.5), but other process in addition to 
diffusion are important. There is also a relaxation of the polymer chain, which influences 
the drug release mechanism. This process is described as non- fickian or anomalous 
diffusion (n=0.5-1.0).  Release from initially dry, hydrophilic glassy polymer that swell 
when added to water and become rubbery, show anomalous diffusion as a result of the 
rearrangement of macromolecular chain. The thermodynamics state of the polymer and 
penetrant concentration are responsible for the different type of the diffusion. A third 
class of diffusion is case-II diffusion (n=1), which is a special case of non- Fickian 
diffusion. To obtain kinetic parameter of dissolution profile, data were fitted to different 
kinetic models. 
Colon Targeted Micropellets of Mebeverine HCl                           Results and Discussion 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 125 
 
Table 39: Different Kinetic models for Formulations F1-F9 
Code 
Zero order  First order Higuchi Korsemayer’s-Peppas Best fit 
model 
R2 K0 (mg/h−1) R
2
 
K1 
(h-1) R
2
 
K  
(mg 
h−1/2) 
R2 n 
F1 0.9367 0.7878 0.9358 0.0082 0.8481 2.1188 0.9387 1.1424 Peppas 
F2 0.9362 0.7907 0.9352 0.0082 0.8435 2.1220 0.9375 1.1688 Peppas 
F3 0.9363 0.7610 0.9352 0.0079 0.8410 2.0394 0.9413 1.1892 Peppas 
F4 0.9395 0.8917 0.9386 0.0093 0.8484 2.3955 0.9411 1.1533 Peppas 
F5 0.9407 0.8782 0.9398 0.0092 0.8444 2.3530 0.9408 1.1848 Peppas 
F6 0.9423 0.8490 0.9414 0.0088 0.8441 2.2727 0.9416 1.1975 Zero order 
F7 0.9456 0.7139 0.9455 0.0074 0.8724 1.9362 0.9221 0.9358 zero order 
F8 0.9466 0.7171 0.9468 0.0074 0.8883 1.9568 0.9387 0.9131 First order 
F9 0.9985 0.7197 0.9487 0.0074 0.8869 1.9613 0.9356 0.9099 First order 
 
 
 
                                            Fig. 38: Peppas plot of formulation F1 
 
 
R2= 0.9387 
n = 1.1424 
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                                      Fig. 39: Peppas plot of formulation F2 
 
 
 
                                           Fig. 40: Peppas plot of formulation F3 
R2= 0.9375 
n = 1.1688 
 
R2= 0.9413 
n = 1.1897 
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                                               Fig. 41: Peppas plot of formulation F4 
 
 
         
               Fig. 42: Peppas plot of formulation F5 
 
R2= 0.9411 
n = 1.1533 
 
R2= 0.9408 
n =1.1848 
Colon Targeted Micropellets of Mebeverine HCl                           Results and Discussion 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 128 
 
 
                
                                       Fig. 43: Zero order plot of formulation F6 
 
 
 
      
Fig. 44: Zero order plot of formulation F7 
 
R2= 0.9423 
k =0.8490 
 
R2= 0.9456 
k = 0.7139 
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                                      Fig. 45: First order plot of formulation F8 
  
 
 
                            Fig. 46:  First order plot of formulation F9 
 
  
R2= 0.9468 
k = 0.0074 
 
R2= 0.9487 
k = 0.0074 
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For micropellets, an “n” value near to 0.5 indicates diffusion control and an “n” 
value near to 1 indicates relaxation or erosion control. The intermediate value suggests 
that diffusion and erosion contributes to overall release mechanism. It was also observed 
that highest correlation was found for Peppas log time profile (R2 > 0.99), which 
indicates the drug release via diffusion mechanism from all formulations. 
Drug release from the formulation F7 follows the zero order release mechanism 
because its R2 value nearer to one. 
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9.8. STABILITY STUDIES 
From the results of the above studies it was found that formulation F7 was 
considered as the best formulation amongst the nine formulations. Hence formulation F7 
was selected for stability studies.  
 
9.8.1. Stability studies at the end of First month (30 days): 
9.8.1.1. Content Uniformity:  
 The Percentage drug content of pellets after one month of stability studies was 
studied. The results are within the official limits. The data is shown in Table 40. 
 
Table 40: Drug content of formulation F7 at the end of 1 month of stability 
S. No. Formulation Percentage drug content 
1. F7          98.50±0.030 
        All the values are expressed as a mean ± SD., n = 3 
 
9.8.1.2. In-vitro drug release study:  
 The Cumulative Percentage Drug Release from F7 micropellets after one month 
of stability was studied. The data is shown in Table 41. 
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Table 41:  In-vitro drug release data of formulation F7 at the end of 1 month of 
stability 
S. 
No. Medium 
Time 
(hours) 
% Drug 
Release 
Amount 
of drug 
released 
(mg) 
%DE MDT (hrs) 
Cumulative 
% drug 
Release  
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 5.60±0.025 0.84 2.10 0.50 5.60 3 2 6.32±0.015 0.90 3.23 0.57 11.92 
4 pH 6.8 
phosphate 
buffer 
3 9.78±0.010 1.19 3.90 1.03 15.38 
5 4 16.13±0.020 1.71 4.74 1.79 21.73 
6 5 20.00±0.015 2.04 5.67 2.22 25.6 
7 
pH 7.4 
phosphate 
buffer  
6 54.17±0.025 4.83 7.59 4.12 59.77 
8 7 73.35±0.025 6.42 10.52 4.71 78.95 
9 8 77.98±0.021 6.83 13.35 4.87 83.58 
10 10 81.99±0.020 7.20 17.69 5.08 87.59 
11 12 83.73±0.015 7.29 20.78 5.16 89.30 
All the values are expressed as a mean ± SD., n = 3 
 
 
   Fig.47. In-vitro drug release profile of formulation F7 at the end of 1 month of 
stability 
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9.8.2. Stability studies at the end of Second month (60 days): 
9.8.2.1. Drug content:  
 The Percentage drug content of pellets after Two months of stability studies was 
studied. The results are within the official limits. The data is shown in Table 42. 
Table 42: Drug content of formulation F7 at the end of 2 months of stability 
Sl. No. Formulation Percentage drug content 
1. F7 98.15±0.025 
      All the values are expressed as a mean ± SD., n = 3 
9.8.2.2. In-vitro drug release study:  
 The Cumulative Percentage Drug Release from F7 pellets after Two months of 
stability was studied. The data is shown in Table 43. 
Table 43: In-vitro drug release data of formulation F7 at the end of 2 months of 
stability 
Sl. 
No. Medium 
Time 
(hours) 
% Drug 
Release 
Amount 
of drug 
released 
(mg) 
%DE MDT (hrs) 
Cumulative 
% drug 
Release  
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 5.59±0.025 0.84 2.10 0.50 5.59 3 2 6.31±0.015 0.90 3.23 0.57 11.9 
4 pH 6.8 
phosphate 
buffer 
3 9.77±0.010 1.19 3.90 1.03 15.36 
5 4 16.10±0.020 1.71 4.74 1.79 21.69 
6 5 19.99±0.015 2.04 5.67 2.22 25.58 
7 
pH 7.4 
phosphate 
buffer  
6 54.15±0.025 4.83 7.59 4.12 59.74 
8 7 73.33±0.025 6.42 10.52 4.71 78.92 
9 8 77.96±0.021 6.83 13.35 4.87 83.55 
10 10 81.97±0.020 7.20 17.69 5.08 87.56 
11 12 83.71±0.015 7.29 20.78 5.16 89.15 
  All the values are expressed as a mean ± SD., n = 3         
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Fig.48. In-vitro drug release profile of formulation F7 at the end of 2 months of 
stability 
9.8.3. Stability studies at the end of Third month (90 days): 
9.8.3.1 Drug content:  
 The Percentage drug content of pellets after Third month of stability studies was 
studied. The results are within the official limits. The data is shown in Table 44. 
Table 44: Drug content of formulation F7 at the end of 3 months of stability 
 Sl. No. Formulation Percentage drug content 
1. F7 97.75±0.020 
     All the values are expressed as a mean ± SD., n = 3 
9.8.3.2. In-vitro drug release study:  
 The Cumulative Percentage Drug Release from F7 pellets after Two months of 
stability was studied. The data is shown in Table 45. 
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Table 45: In-vitro drug release data of formulation F7 at the end of 3 months of 
stability 
Sl. 
No. Medium 
Time 
(hours) 
% Drug 
Release 
Amount 
of drug 
released 
(mg) 
%DE MDT (hrs) 
Cumulative 
% drug 
Release  
1  0 0 0.00 0.00 0.00 0 
2 0.1N HCl 1 5.57±0.025 0.84 2.10 0.50 5.57 3 2 6.29±0.015 0.90 3.23 0.57 11.86 
4 pH 6.8 
phosphate 
buffer 
3 9.76±0.010 1.19 3.90 1.03 15.33 
5 4 16.08±0.020 1.71 4.74 1.79 21.65 
6 5 19.97±0.015 2.04 5.67 2.22 25.54 
7 
pH 7.4 
phosphate 
buffer  
6 54.14±0.025 4.83 7.59 4.12 59.71 
8 7 73.30±0.025 6.42 10.52 4.71 78.87 
9 8 77.90±0.021 6.83 13.35 4.87 83.47 
10 10 81.87±0.020 7.20 17.69 5.08 87.44 
11 12 82.50±0.015 7.29 20.78 5.16 88.92 
      All the values are expressed as a mean ± SD., n = 3 
 
 
      Fig.49. In-vitro drug release profile of formulation F7 at the end of 3months of 
stability 
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Fig.50. Comparison of drug content for formulation F7 with initial and different 
periods of stability 
 
 
 
Fig.51. Comparison of cumulative percentage drug released at the end of 12 hours 
for formulation F7with initial and different periods of stability 
No statistically significant differences were observed in percentage drug content 
and cumulative percentage drug release in optimized formulation at the end of three 
months of stability studies. So it can be concluded that the formulation is stable for short 
term storage conditions. 
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10. SUMMARY AND CONCLUSION 
 
A successful colon targeted drug delivery system was developed with the 
triggering mechanism that responds to the physiological conditions particular to colon.  
The colon targeted micropellets of Mebeverine HCl were prepared by using 
polymers like HPMC K4M, Eudragit L100 and Eudragit S100 for the treatment of IBD. 
The dissolution study of F7 Micropellets containing Eudragit L100 and Eudragit S100 
was concluded the best formulation among other formulations, which showing the most 
desired drug release. It will be considered as optimized formulation. 
The optimized formulation F7 was subjected for stability studies, the formulation 
was found to be stable in short term stability study. 
From the in-vitro drug release data, it can be concluded that the HPMC K4M, 
Eudragit L100 and Eudragit S100 are capable of protecting the drug from being released 
in Stomach and in Small Intestine. This retardant capacity is more in F7 as compared to 
other formulations. 
During the in-vitro drug release study, on exposure to the dissolution fluid, the 
micropellets slows down further seeping-in of dissolution fluids towards the interior of 
the pellets. Once the gel layer is formed the drug release takes place mainly by diffusion 
from the inner region. On reaching the colonic environment the polymeric layer would 
soluble at colonic pH and release the major amount of drug in the region of colon.  
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In the in-vitro drug release study, the drug release from the micropellets required 
a longer time in experimental conditions. But in actual use in living systems these 
limitations for pH environment and it will never be felt. Therefore the micropellets will 
be take place completely and rapidly in the colon region. 
While analyzing the drug release pattern of the drug from the micropellets, it was 
found that the drug release started in the early hours of study. This was due to change in 
pH. 
Out of the nine formulations, it appears that F7 has the maximum potential in 
providing colon targeted drug delivery.  
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11. FUTURE PROSPECTS 
 
In this work only physic-chemical characterization and in-vitro evaluation of 
Mebeverine HCl micropellets were done.  
1. Along with in-vitro release study in-vivo release studies are also important. So in 
future in-vivo release study using different models are required to set the in-vitro 
in-vivo correlation which is necessary for development of successful formulation 
and also long term stability studies are necessary. 
2. Study the effect of various geometric shapes, in a more excessive manner than 
previous studies, extended dimensions. 
3. Design of novel polymers according to clinical and pharmaceutical need. 
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